Document:

EX-10.46

 Exhibit 10.46 
 REGADO BIOSCIENCES, INC. 
 LOAN AND SECURITY AGREEMENT 

 This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of May 10, 2013, by
and between COMERICA BANK (“Bank”) and REGADO BIOSCIENCES, INC. (“Borrower”). 
 RECITALS

 Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets
forth the terms on which Bank will advance credit to Borrower, and Borrower will repay the amounts owing to Bank. 

AGREEMENT 
 The
parties agree as follows: 
  

	 	1.	DEFINITIONS AND CONSTRUCTION. 

 1.1 Definitions. As used in this Agreement, all capitalized terms shall have the definitions set forth on Exhibit A. Any term used in the Code and not defined herein shall have the meaning given to
the term in the Code. 
 1.2 Accounting Terms. Any accounting term not specifically defined on Exhibit A shall be
construed in accordance with GAAP and all calculations shall be made in accordance with GAAP. The term “financial statements” shall include the accompanying notes and schedules. 

 

	 	2.	LOAN AND TERMS OF PAYMENT. 

2.1 Credit Extensions. 
 (a) Promise to Pay. Borrower promises to pay to Bank, in lawful money of the United States of America, the aggregate unpaid principal amount of all Credit Extensions made by Bank to Borrower,
together with interest on the unpaid principal amount of such Credit Extensions at rates in accordance with the terms hereof. 

(b) Growth Capital Advances. 
 (i) Subject to and upon the terms and conditions of this Agreement, Borrower may request two Growth Capital Advances as follows: (i) Borrower may request the initial Growth Capital Advance in an
amount equal to $4,500,000 on the Closing Date (the “Tranche A Growth Capital Advance”), and (ii) upon Bank’s receipt of evidence reasonably satisfactory to Bank that the Tranche B Milestones have been achieved, Borrower may,
until the earlier of (x) 30 days after achievement of the Tranche B Milestones and (y) May 30, 2014 request the second Growth Capital Advance in an amount equal to $4,000,000 (the “Tranche B Growth Capital Advance”). The
aggregate outstanding amount of Growth Capital Advances shall not exceed the Growth Capital Line. As used herein, achievement of the “Tranche B Milestones” means Bank’s receipt of evidence reasonably satisfactory to Bank that
(i) the 1000 patient interim analysis in the REGULATE-PCI study has been completed and the interim analysis is successful and performed by April 30, 2014, and (ii) Borrower completed its initial public offering and received net cash
proceeds of at least $50,000,000 from such initial public offering prior to June 30, 2013. 
 (ii) Interest shall accrue
from the date of each Growth Capital Advance at the rate specified in Section 2.3(a), and shall be payable monthly in accordance with Section 2.3(c). Any Growth Capital Advances that are outstanding on August 10, 2014 shall be payable
in equal monthly installments of principal, plus all accrued interest, beginning on September 1, 2014, and continuing on the same day of each month 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 1	  	May 10, 2013            

 
thereafter through the Growth Capital Maturity Date at which time all Growth Capital Advances and any other amounts due under this Agreement shall be immediately due and payable. Growth Capital
Advances, once repaid, may not be reborrowed. Except as set forth in the Prime Reference Rate Addendum, Borrower may prepay any Growth Capital Advances without penalty or premium. 

(iii) When Borrower desires to obtain a Growth Capital Advance, Borrower shall notify Bank (which notice shall be irrevocable) by
facsimile transmission to be received no later than 3:00 p.m. Pacific time three (3) Business Days before the day on which the Growth Capital Advance is to be made. Such notice shall be substantially in the form of Exhibit C. The notice
shall be signed by a Responsible Officer or its designee. Bank shall be entitled to rely on any facsimile or telephonic notice given by a person who Bank reasonably believes to be a Responsible Officer or a designee thereof, and Borrower shall
indemnify and hold Bank harmless for any damages or loss suffered by Bank as a result of such reliance. 
 2.2
[Reserved]. 
 2.3 Interest Rates, Payments, and Calculations. 

(a) Interest Rates. 
 (i) Growth Capital Advances. Except as set forth in Section 2.3(b), the Growth Capital Advances shall bear interest, on the outstanding daily balance thereof, as set forth in the Prime
Reference Rate Addendum. 
 (b) Late Fee; Default Rate. If any payment is not made within 10 days after the date such
payment is due, Borrower shall pay Bank a late fee equal to the lesser of (i) five percent (5%) of the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. All Obligations shall bear
interest, from and after the occurrence and during the continuance of an Event of Default, at a rate equal to five (5) percentage points above the interest rate applicable immediately prior to the occurrence of the Event of Default. 

(c) Payments. Except as set forth in the Prime Reference Rate Addendum, interest hereunder shall be due and payable on the first
calendar day of each month during the term hereof. Bank shall, at its option, charge such interest, all Bank Expenses, and all Periodic Payments against any of Borrower’s deposit accounts or against the Growth Capital Line, in which case those
amounts shall thereafter accrue interest at the rate then applicable hereunder. Any interest not paid when due shall be compounded by becoming a part of the Obligations, and such interest shall thereafter accrue interest at the rate then applicable
hereunder. Payments hereunder shall be made via auto debit from Borrower’s account at Bank. 
 (d) Computation.
With respect to Obligations bearing interest at the Prime Rate, in the event the Prime Rate is changed from time to time hereafter, the applicable rate of interest hereunder shall be increased or decreased, effective as of the day the Prime Rate is
changed, by an amount equal to such change in the Prime Rate. All interest chargeable under the Loan Documents shall be computed on the basis of a three hundred sixty (360) day year for the actual number of days elapsed. 

2.4 Crediting Payments. Prior to the occurrence of an Event of Default, Bank shall credit a wire transfer of funds, check or other
item of payment to such deposit account or Obligation as Borrower specifies. After and during the continuance of an Event of Default, Bank shall have the right, in its sole discretion, to immediately apply any wire transfer of funds, check, or other
item of payment Bank may receive to conditionally reduce Obligations, but such applications of funds shall not be considered a payment on account unless such payment is of immediately available federal funds or unless and until such check or other
item of payment is honored when presented for payment. Notwithstanding anything to the contrary contained herein, any wire transfer or payment received by Bank after 12:00 noon Pacific time shall be deemed to have been received by Bank as of the

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 2	  	May 10, 2013            

 
opening of business on the immediately following Business Day. Whenever any payment to Bank under the Loan Documents would otherwise be due (except by reason of acceleration) on a date that is
not a Business Day, such payment shall instead be due on the next Business Day, and additional fees or interest, as the case may be, shall accrue and be payable for the period of such extension. 

2.5 Fees. Borrower shall pay to Bank the following: 
 (a) Commitment Fee. On or prior to the Closing Date, a fee equal to $85,000, which shall be nonrefundable; 
 (b) Final Payment. On the earlier of (i) the Growth Capital Maturity Date or (ii) the prepayment, acceleration or termination of the Growth Capital Line or this Agreement, in addition to
the outstanding principal, accrued and unpaid interest, and all other amounts due on such date with respect to the Growth Capital Line, an amount equal to the Final Payment; and 

(c) Bank Expenses. On the Closing Date, all Bank Expenses incurred through the Closing Date and, after the Closing Date, all Bank
Expenses, as and when they become due. 
 2.6 Term. This Agreement shall become effective on the Closing Date and,
subject to Section 13.8, shall continue in full force and effect for so long as any Obligations remain outstanding or Bank has any obligation to make Credit Extensions under this Agreement. Notwithstanding the foregoing, Bank shall have the
right to terminate its obligation to make Credit Extensions under this Agreement immediately and without notice upon the occurrence and during the continuance of an Event of Default. Upon full and final payment of all Obligations (except inchoate
indemnification obligations with respect to which no claims have been asserted in writing) and provided Bank has no further obligation to make any Credit Extension, this Agreement shall, upon written request by Borrower, terminate (except as to
provisions hereof which by their express terms survive termination of this Agreement). 
  

	 	3.	CONDITIONS OF LOANS. 

 3.1
Conditions Precedent to Initial Credit Extension. The obligation of Bank to make the initial Credit Extension is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, the following:

 (a) this Agreement; 
 (b) an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution and delivery of this Agreement; 

(c) Prime Reference Rate Addendum; 
 (d) a financing statement (Form UCC-1); 
 (e) agreement to furnish insurance;

 (f) payment of the fees and Bank Expenses then due specified in Section 2.5; 

(g) current SOS Reports indicating that except for Permitted Liens, there are no other security interests or Liens of record in the
Collateral; 
 (h) warrant to purchase stock; 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 3	  	May 10, 2013            

 (i) a payoff letter from Midcap Financial SBIC, LP; 

(j) Control agreement with State Street Bank; 
 (k) a landlord waiver, duly executed by the landlord of Borrower’s 1307 Person Street Durham, North Carolina location; 
 (l) a bailee waiver, duly executed by Biostorage Technologies, Inc.; 
 (m)
evidence satisfactory to Bank that Borrower closed, prior to April 30, 2013, the second tranche of its Series E Preferred Stock financing and received net cash proceeds of at least $10,000,000 from such financing; 

(n) current financial statements in accordance with Section 6.2, and such other updated financial information as Bank may
reasonably request; 
 (o) current Compliance Certificate in accordance with Section 6.2; 

(p) a Collateral Information Certificate; 
 (q) an Automatic Debit Authorization; and 
 (r) such other documents or
certificates, and completion of such other matters, as Bank may reasonably deem necessary or appropriate. 
 3.2 Post Closing
Conditions. Unless otherwise provided by Bank in writing, Borrower shall deliver to Bank, in form and substance satisfactory to Bank: 
 (a) within three (3) days of the Closing Date, evidence that all Liens against Borrower in favor of Midcap Financial SBIC, LP, as agent for the lenders, have been terminated and released; and

 (b) within thirty (30) days of the Closing Date, a landlord waiver, duly executed by the landlord and subtenant of
Borrower’s 120 Mountain View Boulevard, Basking Ridge, New Jersey location. 
 3.3 Conditions Precedent to all Credit
Extensions. The obligation of Bank to make each Credit Extension, including the initial Credit Extension, is further subject to the following conditions: 
 (a) timely receipt by Bank of the Payment/Advance Form as provided in Section 2.1; and 
 (b) the representations and warranties contained in Article 5 shall be true and correct in all material respects on and as of the date of such Payment/Advance Form and on the effective date of each Credit
Extension as though made at and as of each such date, and no Event of Default shall have occurred and be continuing, or would exist after giving effect to such Credit Extension (provided, however, that those representations and warranties expressly
referring to another date shall be true, correct and complete in all material respects as of such date). The making of each Credit Extension shall be deemed to be a representation and warranty by Borrower on the date of such Credit Extension as to
the accuracy of the facts referred to in this Section 3.2. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 4	  	May 10, 2013            

	 	4.	CREATION OF SECURITY INTEREST. 

 4.1 Grant of Security Interest. Borrower grants and pledges to Bank a continuing security interest in the Collateral to secure prompt repayment of any and all Obligations and to secure prompt
performance by Borrower of each of its covenants and duties under the Loan Documents. Except as set forth in the Schedule, such security interest constitutes a valid, first priority security interest in the presently existing Collateral, and will
constitute a valid, first priority security interest in later-acquired Collateral. Borrower also hereby agrees not to sell, transfer, assign, mortgage, pledge, lease, grant a security interest in, or encumber any of its Intellectual Property, except
in connection with Permitted Liens and Permitted Transfers. Notwithstanding any termination of this Agreement, Bank’s Lien on the Collateral shall remain in effect for so long as any Obligations are outstanding. Upon full and final payment of
all Obligations (except inchoate indemnification obligations with respect to which no claims have been asserted in writing) and provided Bank has no further obligation to make any Credit Extension, Bank shall, upon written request by Borrower,
promptly release its liens and security interests in the Collateral at Borrower’s sole cost and expense. 
 4.2
Perfection of Security Interest. Borrower authorizes Bank to file at any time financing statements, continuation statements, and amendments thereto that (i) either specifically describe the Collateral or describe the Collateral as all
assets of Borrower of the kind pledged hereunder (but not all assets to the extent the same includes property not constituting Collateral hereunder), and (ii) contain any other information required by the Code for the sufficiency of filing
office acceptance of any financing statement, continuation statement, or amendment, including whether Borrower is an organization, the type of organization and any organizational identification number issued to Borrower, if applicable. Any such
financing statements may be filed by Bank at any time in any jurisdiction whether or not Revised Article 9 of the Code is then in effect in that jurisdiction. Borrower shall from time to time endorse and deliver to Bank, at the request of Bank, all
Negotiable Collateral and other documents that Bank may reasonably request, in form satisfactory to Bank, to perfect and continue perfection of Bank’s security interests in the Collateral and in order to fully consummate all of the transactions
contemplated under the Loan Documents. Borrower shall have possession of the Collateral, except where expressly otherwise provided in this Agreement or where Bank chooses to perfect its security interest in Investment Property by possession in
addition to the filing of a financing statement. Where Collateral is in possession of a third party bailee, Borrower shall take such steps as Bank reasonably requests for Bank to (i) obtain an acknowledgment, in form and substance satisfactory
to Bank, of the bailee that the bailee holds such Collateral for the benefit of Bank, (ii) obtain “control” of any Collateral consisting of investment property, deposit accounts, letter-of-credit rights or electronic chattel paper (as such
items and the term “control” are defined in Revised Article 9 of the Code) by causing the securities intermediary or depositary institution or issuing bank to execute a control agreement in form and substance satisfactory to Bank. Borrower
will not create any chattel paper without placing a legend on the chattel paper acceptable to Bank indicating that Bank has a security interest in the chattel paper. Borrower from time to time may deposit with Bank specific cash collateral to secure
specific Obligations; Borrower authorizes Bank to hold such specific balances in pledge and to decline to honor any drafts thereon or any request by Borrower or any other Person to pay or otherwise transfer any part of such balances for so long as
the specific Obligations are outstanding. 
 4.3 Right to Inspect. Bank (through any of its officers, employees, or
agents) shall have the right, upon reasonable prior notice, from time to time during Borrower’s usual business hours but no more than twice a year (unless an Event of Default has occurred and is continuing), to inspect Borrower’s Books and
to make copies thereof and to check, test, and appraise the Collateral in order to verify Borrower’s financial condition or the amount, condition of, or any other matter relating to, the Collateral. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 5	  	May 10, 2013            

	 	5.	REPRESENTATIONS AND WARRANTIES. 

 Borrower represents and warrants as follows: 
 5.1 Due Organization and
Qualification. Borrower and each Subsidiary is an entity duly existing under the laws of the jurisdiction in which it is organized and qualified and licensed to do business in any state in which the conduct of its business or its ownership of
property requires that it be so qualified, except where the failure to do so could not reasonably be expected to cause a Material Adverse Effect. 
 5.2 Due Authorization; No Conflict. The execution, delivery, and performance of the Loan Documents are within Borrower’s powers, have been duly authorized, and are not in conflict with nor
constitute a breach of any provision contained in Borrower’s organizational documents, nor will they constitute an event of default under any material agreement by which Borrower is bound. Borrower is not in default under any agreement by which
it is bound, except to the extent such default would not reasonably be expected to cause a Material Adverse Effect. 
 5.3
Collateral. Borrower has rights in or the power to transfer the Collateral, and its title to the Collateral is free and clear of Liens, adverse claims, and restrictions on transfer or pledge except for Permitted Liens. Except for portable
office equipment and communications devices such as laptops, cellphones, BlackBerries and the like with an aggregate value not to exceed $25,000, all Collateral is located solely in the Collateral States. All Inventory is in all material respects of
good and merchantable quality, free from all material defects, except for Inventory for which adequate reserves have been made. Except as set forth in the Schedule, none of the Collateral is maintained or invested with a Person other than Bank or
Bank’s Affiliates. 
 5.4 Intellectual Property. Borrower is the sole owner of the Intellectual Property to the
extent of Borrower’s interest therein, except for licenses granted by Borrower to its customers in the ordinary course of business. Borrower has no knowledge that Borrower’s Copyrights, Trademarks and Patents are not valid and enforceable.
No part of Borrower’s Intellectual Property has been judged invalid or unenforceable, in whole or in part, and no claim has been made to Borrower in writing that any part of Borrower’s Intellectual Property violates the rights of any third
party except to the extent such claim could not reasonably be expected to cause a Material Adverse Effect. Borrower has received no written notice that any patents, trademarks or copyrights licensed to Borrower have been judged invalid or
unenforceable, in whole or in part, or that any claim has been made that any part of such patents, trademarks or copyrights violates the rights of any third party except to the extent such claim could not reasonably be expected to cause a Material
Adverse Effect. 
 5.5 Name; Location of Chief Executive Office. Except as disclosed in the Schedule, Borrower has not
done business under any name other than that specified on the signature page hereof, and its exact legal name is as set forth in the first paragraph of this Agreement. The chief executive office of Borrower is located in the Chief Executive Office
State at the address indicated in Section 10 hereof. 
 5.6 Actions, Suits, Litigation, or Proceedings. Except as
set forth in the Schedule, as updated from time to time, there are no actions, suits, litigation or proceedings, at law or in equity, pending by or against Borrower or any Subsidiary before any court, administrative agency, or arbitrator in which an
adverse decision is likely and could reasonably be expected to have a Material Adverse Effect. 
 5.7 No Material Adverse
Change in Financial Statements. All consolidated and consolidating financial statements related to Borrower and any Subsidiary that are delivered by Borrower to Bank fairly present in all material respects Borrower’s consolidated and
consolidating financial condition as of the date thereof and Borrower’s consolidated and consolidating results of operations for the period then ended. There has not been a material adverse change in the consolidated or in the consolidating
financial condition of Borrower since the date of the most recent of such financial statements submitted to Bank. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 6	  	May 10, 2013            

 5.8 Solvency, Payment of Debts. Borrower is able to pay its debts (including trade
debts) as they mature; the fair saleable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; and Borrower is not left with unreasonably small capital after the transactions
contemplated by this Agreement. 
 5.9 Compliance with Laws and Regulations. Borrower and each Subsidiary have met the
minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. No event has occurred resulting from Borrower’s failure to comply with ERISA that is reasonably likely to result in Borrower’s incurring any
liability that could reasonably be expected to have a Material Adverse Effect. Borrower is not an “investment company” or a company “controlled” by an “investment company” within the meaning of the Investment Company
Act of 1940. Borrower is not engaged principally, or as one of the important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulations T and U of the Board of Governors
of the Federal Reserve System). Borrower has complied in all material respects with all the provisions of the Federal Fair Labor Standards Act. Borrower is in compliance with all environmental laws, regulations and ordinances except where the
failure to comply is not reasonably likely to have a Material Adverse Effect. Borrower has not violated any statutes, laws, ordinances or rules applicable to it, the violation of which could reasonably be expected to have a Material Adverse Effect.
Borrower and each Subsidiary have filed or caused to be filed all tax returns required to be filed, and have paid, or have made adequate provision for the payment of, all taxes reflected therein except those being contested in good faith with
adequate reserves under GAAP or where the failure to file such returns or pay such taxes could not reasonably be expected to have a Material Adverse Effect. 
 5.10 Subsidiaries. Borrower does not own any stock, partnership interest or other equity securities of any Person, except for Permitted Investments. 

5.11 Government Consents. Borrower and each Subsidiary have obtained all consents, approvals and authorizations of, made all
declarations or filings with, and given all notices to, all governmental authorities that are necessary for the continued operation of Borrower’s business as currently conducted, except where the failure to do so would not reasonably be
expected to cause a Material Adverse Effect. 
 5.12 Inbound Licenses. Except as disclosed on the Schedule, as updated
from time to time, Borrower is not a party to, nor is bound by, any material inbound license or other similar agreement (other than off the shelf licenses), the failure, breach, or termination of which could reasonably be expected to cause a
Material Adverse Effect, or that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or any other property. 

5.13 Full Disclosure. No representation, warranty or other statement made by Borrower in any certificate or written statement
furnished to Bank taken together with all such certificates and written statements furnished to Bank contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained in such
certificates or statements not misleading, it being recognized by Bank that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not to be viewed as facts and that actual results during the
period or periods covered by any such projections and forecasts may differ from the projected or forecasted results. 
 5.14
No Material Adverse Effect. No Material Adverse Effect or event reasonably expected to cause a Material Adverse Effect has occurred. As of the date hereof, there is in effect no Clinical Hold. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 7	  	May 10, 2013            

	 	6.	AFFIRMATIVE COVENANTS. 

Borrower covenants that, until payment in full of all outstanding Obligations, and for so long as Bank may have any commitment to make a
Credit Extension hereunder, Borrower shall do all of the following: 
 6.1 Good Standing and Government Compliance.
Borrower shall maintain its and each of its Subsidiaries’ organizational existence and good standing in the Borrower State, shall maintain qualification and good standing in each other jurisdiction in which the failure to so qualify could
reasonably be expected to have a Material Adverse Effect, and shall furnish to Bank the organizational identification number issued to Borrower by the authorities of the jurisdiction in which Borrower is organized, if applicable. Borrower shall
meet, and shall cause each Subsidiary to meet, the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. Borrower shall comply in all material respects with all applicable Environmental Laws, and maintain
all material permits, licenses and approvals required thereunder where the failure to do so could reasonably be expected to have a Material Adverse Effect. Borrower shall comply, and shall cause each Subsidiary to comply, with all statutes, laws,
ordinances and government rules and regulations to which it is subject, and shall maintain, and shall cause each of its Subsidiaries to maintain, in force all licenses, approvals and agreements, the loss of which or failure to comply with which
would reasonably be expected to have a Material Adverse Effect. 
 6.2 Financial Statements, Reports, Certificates.
Borrower shall deliver to Bank: (i) as soon as available, but in any event within thirty (30) days after the end of each calendar month, a company prepared consolidated and consolidating balance sheet and income statement covering
Borrower’s operations during such period, in a form reasonably acceptable to Bank and certified by a Responsible Officer; (ii) as soon as available, but in any event within one hundred eighty (180) days after the end of
Borrower’s fiscal year, audited consolidated and consolidating financial statements of Borrower prepared in accordance with GAAP, consistently applied, together with an opinion which is unqualified (including no going concern comment or
qualification) or otherwise consented to in writing by Bank on such financial statements of an independent certified public accounting firm reasonably acceptable to Bank; (iii) if applicable, copies of all statements, reports and notices sent
or made available generally by Borrower to its security holders or to any holders of Subordinated Debt and all reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission; (iv) promptly upon receipt of notice thereof, a
report of any legal actions pending or threatened against Borrower or any Subsidiary that could reasonably be expected to result in damages or costs to Borrower or any Subsidiary of One Hundred Thousand Dollars ($100,000) or more; (v) promptly
upon receipt, each management letter prepared by Borrower’s independent certified public accounting firm regarding Borrower’s management control systems; (vi) as soon as available, but in any event within 30 days from the beginning of
each fiscal year, Borrower’s annual financial and business projections and operating budget for such year, with evidence of approval thereof by Borrower’s board of directors; and (vii) such budgets, sales projections, operating plans
or other financial information generally prepared by Borrower in the ordinary course of business as Bank may reasonably request from time to time. 
 (a) Within thirty (30) days after the last day of each month, Borrower shall deliver to Bank with the monthly financial statements a Compliance Certificate certified as of the last day of the
applicable month and signed by a Responsible Officer in substantially the form of Exhibit D hereto. 
 (b) Promptly upon
becoming aware of the occurrence or existence of an Event of Default hereunder, a written statement of a Responsible Officer setting forth details of the Event of Default, and the action which Borrower has taken or proposes to take with respect
thereto. 
 (c) Bank shall have a right from time to time hereafter to audit Borrower’s Accounts and appraise Collateral
at Borrower’s expense, provided that such audits will be conducted no more often than every six (6) months unless an Event of Default has occurred and is continuing. 
 Borrower may deliver to Bank on an electronic basis any certificates, reports or information required pursuant to this Section 6.2, and Bank shall be entitled to rely on the information contained in
the electronic files, provided that Bank in good faith believes that the files were delivered by a Responsible Officer. If Borrower delivers this information electronically, it shall also deliver to Bank by U.S. Mail, reputable overnight courier
service, hand delivery, facsimile or .pdf file within five (5) Business Days of submission of the unsigned electronic copy the certification of monthly financial statements and the Compliance Certificate, each bearing the physical signature of the
Responsible Officer. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 8	  	May 10, 2013            

 6.3 Inventory; Returns. Borrower shall use commercially reasonable efforts to keep
all Inventory in good and merchantable condition, free from all material defects except for Inventory for which adequate reserves have been made. Returns and allowances, if any, as between Borrower and its account debtors shall be on the same basis
and in accordance with the usual customary practices of Borrower, as they exist on the Closing Date. Borrower shall promptly notify Bank of all returns and recoveries and of all disputes and claims involving more than One Hundred Thousand
($100,000). 
 6.4 Taxes. Borrower shall make, and cause each Subsidiary to make, due and timely payment or deposit of
all material federal, state, and local taxes, assessments, or contributions required of it by law, including, but not limited to, those laws concerning income taxes, F.I.C.A., F.U.T.A. and state disability, and will execute and deliver to Bank, on
demand, proof satisfactory to Bank indicating that Borrower or a Subsidiary has made such payments or deposits and any appropriate certificates attesting to the payment or deposit thereof; provided that Borrower or a Subsidiary need not make any
payment if the amount or validity of such payment is contested in good faith by appropriate proceedings and is reserved against (to the extent required by GAAP) by Borrower. 
 6.5 Insurance. 
 (a) Borrower, at its expense, shall keep the Collateral
insured against loss or damage by fire, theft, explosion, sprinklers, and all other hazards and risks, and in such amounts, as ordinarily insured against by other owners in similar businesses conducted in the locations where Borrower’s business
is conducted on the date hereof. Borrower shall also maintain liability and other insurance in amounts and of a type that are customary to businesses similar to Borrower’s. 

(b) All such policies of insurance shall be in such form, with such companies, and in such amounts as reasonably satisfactory to Bank.
All policies of property insurance shall contain a lender’s loss payable endorsement, in a form reasonably satisfactory to Bank, showing Bank as an additional loss payee, and all liability insurance policies shall show Bank as an additional
insured and specify that the insurer must give at least twenty (20) days notice to Bank before canceling its policy for any reason. Upon Bank’s request, Borrower shall deliver to Bank certified copies of the policies of insurance and
evidence of all premium payments. If no Event of Default has occurred and is continuing, proceeds payable under any casualty policy will, at Borrower’s option, be payable to Borrower to replace the property subject to the claim, provided that
any such replacement property shall be deemed Collateral in which Bank has been granted a first priority security interest, subject only to Permitted Liens, as applicable. If an Event of Default has occurred and is continuing, all proceeds payable
under any such policy shall, at Bank’s option, be payable to Bank to be applied on account of the Obligations. 
 6.6
Accounts. Beginning within thirty (30) days after the Closing Date and at all times thereafter, Borrower shall maintain all its depository, operating and investment accounts Bank provided however that Borrower may maintain an
account with State Street Bank provided such account is subject at all times to a control agreement in form satisfactory to Bank. Borrower shall, within thirty (30) days after the Closing Date, close its account with Square 1 Bank and transfer
all funds to Bank. 
 6.7 Financial Covenants. [None]. 

6.8 Registration of Intellectual Property Rights. 
 (a) Borrower shall register or cause to be registered (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as the case may be,
those registrable intellectual property rights now owned or hereafter developed or acquired by Borrower, to the extent that Borrower, in its reasonable business judgment, deems it appropriate to so protect such intellectual property rights.

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 9	  	May 10, 2013            

 (b) Borrower shall, no less frequently than quarterly, give Bank written notice of any
applications or registrations of intellectual property rights filed with the United States Patent and Trademark Office, including the date of such filing and the registration or application numbers, if any. 

(c) Borrower shall give Bank prompt written notice of the filing of any applications or registrations with the United States Copyright
Office, including the title of such intellectual property rights to be registered, as such title will appear on such applications or registrations, and the date such applications or registrations will be filed. 

(d) Borrower shall in its reasonable business judgment (i) protect, defend and maintain the validity and enforceability of the
material Trademarks, Patents, Copyrights, and trade secrets, (ii) use commercially reasonable efforts to detect infringements of the material Trademarks, Patents and Copyrights and promptly advise Bank in writing of material infringements
detected and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public without the written consent of Bank, which shall not be unreasonably withheld. 

6.9 Landlord Waivers. Borrower shall obtain and deliver to Bank a landlord waiver in form satisfactory to Bank for each location
at which Borrower leases property and maintains personal property with an aggregate value in excess of Fifteen Thousand Dollars ($15,000), duly executed by the landlord of each such location (provided that Borrower shall not be required to obtain a
landlord waiver for Borrower’s location at 1000 Centre Green Way, Cary, North Carolina provided the lease for such location terminates and expires on May 31, 2013 and is not renewed or otherwise extended). 

6.10 Further Assurances. At any time and from time to time Borrower shall execute and deliver such further instruments and take
such further action as may reasonably be requested by Bank to effect the purposes of this Agreement. 
  

	 	7.	NEGATIVE COVENANTS. 

Borrower covenants and agrees that, so long as any credit hereunder shall be available and until the outstanding Obligations are paid in
full or for so long as Bank may have any commitment to make any Credit Extensions, Borrower will not do any of the following without Bank’s prior written consent: 
 7.1 Dispositions. Convey, sell, lease, license, transfer or otherwise dispose of (collectively, to “Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its
business or property, or subject to Section 6.6 of the Agreement, move cash balances on deposit with Bank to accounts opened at another financial institution, other than Permitted Transfers. 

7.2 Change in Name, Location, Executive Office, or Executive Management; Change in Business; Change in Fiscal Year; Change in
Control. Change its name or the Borrower State or relocate its chief executive office without thirty (30) days prior written notification to Bank; replace its chief executive officer or chief financial officer without written notice to Bank
promptly thereafter; engage in any business, or permit any of its Subsidiaries to engage in any business, other than or reasonably related or incidental to the businesses currently engaged in by Borrower; change its fiscal year end; have a Change in
Control. 
 7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate,
with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or
property of another Person, or enter into any agreement to do any of the same except where (i) such transactions do not in the aggregate exceed One Hundred Thousand Dollars ($100,000) during any fiscal year, (ii) no Event of Default has occurred, is
continuing or would exist after giving effect to such transactions, (iii) such transactions do not result in a Change in Control, and (iv) Borrower is the surviving entity. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 10	  	May 10, 2013            

 7.4 Indebtedness. Create, incur, assume, guarantee or be or remain liable with
respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except Indebtedness to Bank.

 7.5 Encumbrances. Create, incur, assume or allow any Lien with respect to any of its property, or assign or otherwise
convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries so to do, except for Permitted Liens, or covenant to any other Person that Borrower in the future will refrain from creating, incurring,
assuming or allowing any Lien with respect to any of Borrower’s property. 
 7.6 Distributions. Pay any dividends or
make any other distribution or payment on account of or in redemption, retirement or purchase of any capital stock, except that Borrower may repurchase the stock of former employees pursuant to stock repurchase agreements as long as an Event of
Default does not exist prior to such repurchase or would not exist after giving effect to such repurchase. 
 7.7
Investments. Directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments, or maintain or invest any of its properly with a Person other than
Bank or Bank’s Affiliates or permit any Subsidiary to do so unless such Person has entered into a control agreement with Bank, in form and substance satisfactory to Bank, or suffer or permit any Subsidiary to be a party to, or be bound by, an
agreement that restricts such Subsidiary from paying dividends or otherwise distributing properly to Borrower. Further, Borrower shall not enter into any license or agreement with any Prohibited Territory or with any Person organized under or doing
business in a Prohibited Territory. 
 7.8 Transactions with Affiliates. Directly or indirectly enter into or permit to
exist any material transaction with any Affiliate of Borrower except for transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an
arm’s length transaction with a non-affiliated Person. 
 7.9 Subordinated Debt. Make any payment in respect of any
Subordinated Debt, or permit any of its Subsidiaries to make any such payment, except in compliance with the terms of such Subordinated Debt and the terms of the subordination agreement relating to such Subordinated Debt, or amend any provision of
any document evidencing such Subordinated Debt, except in compliance with the terms of the subordination agreement relating to such Subordinated Debt, or amend any provision affecting Bank’s rights contained in any documentation relating to the
Subordinated Debt without Bank’s prior written consent. 
 7.10 Inventory and Equipment. Store the Inventory or the
Equipment with a bailee, warehouseman, or similar third party unless the third party has been notified of Bank’s security interest and Bank (a) has received an acknowledgment from the third party that it is holding or will hold the
Inventory or Equipment for Bank’s benefit or (b) is in possession of the warehouse receipt, where negotiable, covering such Inventory or Equipment. Except for Inventory sold in the ordinary course of business and except for such other
locations as Bank may approve in writing, Borrower shall keep the Inventory and Equipment only at the location set forth in Section 10 and such other locations of which Borrower gives Bank prior written notice and as to which Bank files a
financing statement where needed to perfect its security interest. 
 7.11 No Investment Company; Margin Regulation.
Become or be controlled by an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of its important activities, the business of extending credit for the
purpose of purchasing or carrying margin stock, or use the proceeds of any Credit Extension for such purpose. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 11	  	May 10, 2013            

	 	8.	EVENTS OF DEFAULT. 

 Any
one or more of the following events shall constitute an Event of Default by Borrower under this Agreement: 
 8.1 Payment
Default. If Borrower fails to (a) make any payment of principal or interest on any Credit Extension when due, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three
(3) Business Day cure period shall not apply to payments due on the Growth Capital Maturity Date. During the cure period, the failure to make or pay any payment specified under clause (b) hereunder is not an Event of Default (but no Credit
Extension will be made during the cure period); 
 8.2 Covenant Default. 

(a) If Borrower fails to perform any obligation under Article 6 or violates any of the covenants contained in Article 7 of this
Agreement; or 
 (b) If Borrower fails or neglects to perform or observe any other material term, provision, condition,
covenant contained in this Agreement, in any of the Loan Documents, or in any other present or future agreement between Borrower and Bank and as to any default under such other term, provision, condition or covenant that can be cured, has failed to
cure such default within ten (10) days after Borrower receives notice thereof or any officer of Borrower becomes aware thereof; provided, however, that if the default cannot by its nature be cured within the ten (10) day period or cannot
after diligent attempts by Borrower be cured within such ten (10) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional reasonable period (which shall not in any case exceed thirty
(30) days) to attempt to cure such default, so long as Borrower continues to diligently attempt to cure such default, and within such reasonable time period the failure to have cured such default shall not be deemed an Event of Default but no
Credit Extensions will be made; 
 8.3 Material Adverse Change. If there occurs any circumstance or circumstances that
could reasonably be expected to have a Material Adverse Effect; 
 8.4 Defective Perfection. If Bank shall receive at any
time following the Closing Date an SOS Report indicating that except for Permitted Liens, Bank’s security interest in the Collateral is not prior to all other security interests or Liens of record reflected in the report; 

8.5 Attachment. If any material portion of Borrower’s assets is attached, seized, subjected to a writ or distress warrant, or
is levied upon, or comes into the possession of any trustee, receiver or person acting in a similar capacity and such attachment, seizure, writ or distress warrant or levy has not been removed, discharged or rescinded within ten (10) days, or
if Borrower is enjoined, restrained, or in any way prevented by court order from continuing to conduct all or any material part of its business affairs, or if a judgment or other claim becomes a lien or encumbrance upon any material portion of
Borrower’s assets, or if a notice of lien, levy, or assessment is filed of record with respect to any of Borrower’s assets by the United States Government, or any department, agency, or instrumentality thereof, or by any state, county,
municipal, or governmental agency, and the same is not paid within ten (10) days after Borrower receives notice thereof, provided that none of the foregoing shall constitute an Event of Default where such action or event is stayed or an
adequate bond has been posted pending a good faith contest by Borrower (provided that no Credit Extensions will be made during such cure period); 
 8.6 Insolvency. If Borrower becomes insolvent, or if an Insolvency Proceeding is commenced by Borrower, or if an Insolvency Proceeding is commenced against Borrower and is not dismissed or stayed
within forty five (45) days (provided that no Credit Extensions will be made prior to the dismissal of such Insolvency Proceeding); 
 8.7 Other Agreements. If there is a default or other failure to perform in any agreement to which Borrower is a party with a third party or parties resulting in a right by such third party or
parties, whether or not exercised, to accelerate the maturity of any Indebtedness (which shall not include any amounts owed by Borrower as lessee to the lessor in any lease for real property) in an amount in excess of Two Hundred Fifty Thousand
Dollars ($250,000) or that would reasonably be expected to have a Material Adverse Effect; 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 12	  	May 10, 2013            

 8.8 Subordinated Debt. If Borrower makes any payment on account of Subordinated Debt,
except to the extent the payment is allowed under any subordination agreement entered into with Bank; 
 8.9 Judgments;
Settlements. If a judgment or judgments for the payment of money in an amount, individually or in the aggregate, of at least Two Hundred Fifty Thousand Dollars ($250,000) shall be rendered against Borrower and shall remain unsatisfied and
unstayed for a period of ten (10) days (provided that no Credit Extensions will be made prior to the satisfaction or stay of the judgment); or if a settlement or settlements is agreed upon for an amount individually or in the aggregate of at
least Two Hundred Fifty Thousand Dollars ($250,000); or 
 8.10 Misrepresentations. If any material misrepresentation or
material misstatement exists now or hereafter in any warranty or representation set forth herein or in any certificate delivered to Bank by any Responsible Officer pursuant to this Agreement or to induce Bank to enter into this Agreement or any
other Loan Document. 
  

	 	9.	BANK’S RIGHTS AND REMEDIES. 

 9.1 Rights and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may, at its election, without notice of its election and without demand, do any one or more of
the following, all of which are authorized by Borrower: 
 (a) Declare all Obligations, whether evidenced by this Agreement, by
any of the other Loan Documents, or otherwise, immediately due and payable (provided that upon the occurrence of an Event of Default described in Section 8.6 (insolvency), all Obligations shall become immediately due and payable without any
action by Bank); 
 (b) Cease advancing money or extending credit to or for the benefit of Borrower under this Agreement or
under any other agreement between Borrower and Bank; 
 (c) Settle or adjust disputes and claims directly with account debtors
for amounts, upon terms and in whatever order that Bank reasonably considers advisable; 
 (d) Make such payments and do such
acts as Bank considers necessary or reasonable to protect its security interest in the Collateral. Borrower agrees to assemble the Collateral if Bank so requires, and to make the Collateral available to Bank as Bank may designate. Borrower
authorizes Bank to enter the premises where the Collateral is located, to take and maintain possession of the Collateral, or any part of it, and to pay, purchase, contest, or compromise any encumbrance, charge, or lien which in Bank’s
determination appears to be prior or superior to its security interest and to pay all expenses incurred in connection therewith. With respect to any of Borrower’s owned premises, Borrower hereby grants Bank a license to enter into possession of
such premises and to occupy the same, without charge, in order to exercise any of Bank’s rights or remedies provided herein, at law, in equity, or otherwise; 
 (e) Set off and apply to the Obligations any and all (i) balances and deposits of Borrower held by Bank, and (ii) indebtedness at any time owing to or for the credit or the account of Borrower
held by Bank; 
 (f) Ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell
(in the manner provided for herein) the Collateral. Bank is hereby granted a license or other right, 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 13	  	May 10, 2013            

 
solely pursuant to the provisions of this Section 9.1, to use, without charge, Borrower’s labels, patents, copyrights, rights of use of any name, trade secrets, trade names, trademarks,
service marks, and advertising matter, or any property of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Bank’s exercise of its rights
under this Section 9.1, Borrower’s rights under all licenses and all franchise agreements shall inure to Bank’s benefit; 
 (g) Sell the Collateral at either a public or private sale, or both, by way of one or more contracts or transactions, for cash or on terms, in such manner and at such places (including Borrower’s
premises) as Bank determines is commercially reasonable, and apply any proceeds to the Obligations in whatever manner or order Bank deems appropriate. Bank may sell the Collateral without giving any warranties as to the Collateral. Bank may
specifically disclaim any warranties of title or the like. This procedure will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral. If Bank sells any of the Collateral upon credit, Borrower will be
credited only with payments actually made by the purchaser, received by Bank, and applied to the indebtedness of the purchaser. If the purchaser fails to pay for the Collateral, Bank may resell the Collateral and Borrower shall be credited with the
proceeds of the sale; 
 (h) Bank may credit bid and purchase at any public sale; 

(i) Apply for the appointment of a receiver, trustee, liquidator or conservator of the Collateral, without notice and without regard to
the adequacy of the security for the Obligations and without regard to the solvency of Borrower, any guarantor or any other Person liable for any of the Obligations; and 
 (j) Any deficiency that exists after disposition of the Collateral as provided above will be paid immediately by Borrower. 
 Bank may comply with any applicable state or federal law requirements in connection with a disposition of the Collateral and compliance will not be considered adversely to affect the commercial
reasonableness of any sale of the Collateral. 
 9.2 Power of Attorney. Effective only upon the occurrence and during the
continuance of an Event of Default, Borrower hereby irrevocably appoints Bank (and any of Bank’s designated officers, or employees) as Borrower’s true and lawful attorney to: (a) send requests for verification of Accounts or notify
account debtors of Bank’s security interest in the Accounts; (b) endorse Borrower’s name on any checks or other forms of payment or security that may come into Bank’s possession; (c) sign Borrower’s name on any invoice
or bill of lading relating to any Account, drafts against account debtors, schedules and assignments of Accounts, verifications of Accounts, and notices to account debtors; (d) dispose of any Collateral; (e) make, settle, and adjust all
claims under and decisions with respect to Borrower’s policies of insurance; (f) settle and adjust disputes and claims respecting the accounts directly with account debtors, for amounts and upon terms which Bank determines to be
reasonable; and (g) file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Borrower where permitted by law; provided Bank may exercise
such power of attorney to sign the name of Borrower on any of the documents described in clause (g) above, regardless of whether an Event of Default has occurred. The appointment of Bank as Borrower’s attorney in fact, and each and every
one of Bank’s rights and powers, being coupled with an interest, is irrevocable until all of the Obligations have been fully repaid and performed and Bank’s obligation to provide advances hereunder is terminated. 

9.3 Accounts Collection. At any time after the occurrence and during the continuation of an Event of Default, Bank may notify any
Person owing funds to Borrower of Bank’s security interest in such funds and verify the amount of such Account. Borrower shall collect all amounts owing to Borrower for Bank, receive in trust all payments as Bank’s trustee, and immediately
deliver such payments to Bank in their original form as received from the account debtor, with proper endorsements for deposit. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 14	  	May 10, 2013            

 9.4 Bank Expenses. If Borrower fails to pay any amounts or furnish any required proof
of payment due to third persons or entities, as required under the terms of this Agreement, then Bank may do any or all of the following after reasonable notice to Borrower: (a) make payment of the same or any part thereof; (b) set up such
reserves under the Growth Capital Line as Bank deems necessary to protect Bank from the exposure created by such failure; or (c) obtain and maintain insurance policies of the type discussed in Section 6.5 of this Agreement, and take any
action with respect to such policies as Bank deems prudent. Any amounts so paid or deposited by Bank shall constitute Bank Expenses, shall be immediately due and payable, and shall bear interest at the then applicable rate hereinabove provided, and
shall be secured by the Collateral. Any payments made by Bank shall not constitute an agreement by Bank to make similar payments in the future or a waiver by Bank of any Event of Default under this Agreement. 

9.5 Bank’s Liability for Collateral. Bank has no obligation to clean up or otherwise prepare the Collateral for sale. All
risk of loss, damage or destruction of the Collateral shall be borne by Borrower. 
 9.6 No Obligation to Pursue Others.
Bank has no obligation to attempt to satisfy the Obligations by collecting them from any other person liable for them and Bank may release, modify or waive any collateral provided by any other Person to secure any of the Obligations, all without
affecting Bank’s rights against Borrower. Borrower waives any right it may have to require Bank to pursue any other Person for any of the Obligations. 
 9.7 Remedies Cumulative. Bank’s rights and remedies under this Agreement, the Loan Documents, and all other agreements shall be cumulative. Bank shall have all other rights and remedies not
inconsistent herewith as provided under the Code, by law, or in equity. No exercise by Bank of one right or remedy shall be deemed an election, and no waiver by Bank of any Event of Default on Borrower’s part shall be deemed a continuing
waiver. No delay by Bank shall constitute a waiver, election, or acquiescence by it. No waiver by Bank shall be effective unless made in a written document signed on behalf of Bank and then shall be effective only in the specific instance and for
the specific purpose for which it was given. Borrower expressly agrees that this Section 9.7 may not be waived or modified by Bank by course of performance, conduct, estoppel or otherwise. 

9.8 Demand; Protest. Except as otherwise provided in this Agreement, Borrower waives demand, protest, notice of protest, notice of
default or dishonor, notice of payment and nonpayment and any other notices relating to the Obligations. 
  

	 	10.	NOTICES. 

 Unless
otherwise provided in this Agreement, all notices or demands by any party relating to this Agreement or any other agreement entered into in connection herewith shall be in writing and (except for financial statements and other informational
documents which may be sent by first-class mail, postage prepaid) shall be personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return receipt requested, or by telefacsimile to Borrower or to
Bank, as the case may be, at its addresses set forth below: 
  

			
	If to Borrower:	    	 REGADO BIOSCIENCES, INC.
 120
Mountain View Blvd.
 Basking Ridge, NJ 07920
 Attn: Christopher Courts, Chief Financial Officer.
 Fax: XXX XXX XXXX

		
	with a copy to:	    	 Michael J. Lerner, Esq.

Lowenstein Sandler LLP
 65 Livingston
Avenue

		    	 Roseland, New Jersey 07068

FAX: 973-597-2400

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 15	  	May 10, 2013            

			
		
	If to Bank:	    	 Comerica Bank
 M/C
7578
 39200 W. Six Mile Rd.
 Livonia,
MI 48152
 Attn: National Documentation Services

		
	with a copy to:	    	 Comerica Bank
 250 Lytton Ave,
3rd Floor
 Palo Alto, CA 94301
 Attn:
Angela Ong
 FAX: 650-462-6049

 The parties hereto may change the address at which they are to receive notices hereunder, by notice in
writing in the foregoing manner given to the other. 
  

	 	11.	CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER. 

 This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of California, without regard to principles of conflicts of law. Each of Borrower and Bank hereby
submits to the exclusive jurisdiction of the State and Federal courts located in the State of California. THE UNDERSIGNED ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED UNDER CERTAIN CIRCUMSTANCES. TO
THE EXTENT PERMITTED BY LAW, EACH PARTY, AFTER CONSULTING (OR HAVING HAD THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS, HIS OR HER CHOICE, KNOWINGLY AND VOLUNTARILY, AND FOR THE MUTUAL BENEFIT OF ALL PARTIES, WAIVES ANY RIGHT TO TRIAL BY JURY IN
THE EVENT OF LITIGATION ARISING OUT OF OR RELATED TO THIS AGREEMENT OR ANY OTHER DOCUMENT, INSTRUMENT OR AGREEMENT BETWEEN THE UNDERSIGNED PARTIES. 
  

	 	12.	REFERENCE PROVISION. 

12.1 In the event the Jury Trial Waiver set forth above is not enforceable, the parties elect to proceed under this Judicial Reference
Provision. 
 12.2 With the exception of the items specified in Section 12.3, below, any controversy, dispute or claim
(each, a “Claim”) between the parties arising out of or relating to this Agreement or any other document, instrument or agreement between the undersigned parties (collectively in this Section, the “Loan Documents”), will be
resolved by a reference proceeding in California in accordance with the provisions of Sections 638 et seq. of the California Code of Civil Procedure (“CCP”), or their successor sections, which shall constitute the exclusive remedy for the
resolution of any Claim, including whether the Claim is subject to the reference proceeding. Except as otherwise provided in the Loan Documents, venue for the reference proceeding will be in the Superior Court in the County where the real property
involved in the action, if any, is located or in a County where venue is otherwise appropriate under applicable law (the “Court”). 
 12.3 The matters that shall not be subject to a reference are the following: (i) foreclosure of any security interests in real or personal property, (ii) exercise of selfhelp remedies
(including, without limitation, set-off), (iii) appointment of a receiver and (iv) temporary, provisional or ancillary remedies (including, without limitation, writs of attachment, writs of possession, temporary restraining orders or
preliminary injunctions). This Agreement does not limit the right of any party to exercise or oppose any of the rights and remedies described in clauses (i) and (ii) or to seek or oppose from a court of competent jurisdiction any of the
items described in clauses (iii) and (iv). The exercise of, or opposition to, any of those items does not waive the right of any party to a reference pursuant to this Agreement. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 16	  	May 10, 2013            

 12.4 The referee shall be a retired Judge or Justice selected by mutual written agreement of
the parties. If the parties do not agree within ten (10) days of a written request to do so by any party, then, upon request of any party, the referee shall be selected by the Presiding Judge of the Court (or his or her representative). A
request for appointment of a referee may be heard on an ex parte or expedited basis, and the parties agree that irreparable harm would result if ex parte relief is not granted. 

12.5 The parties agree that time is of the essence in conducting the reference proceedings. Accordingly, the referee shall be requested,
subject to change in the time periods specified herein for good cause shown, to (i) set the matter for a status and trial-setting conference within fifteen (15) days after the date of selection of the referee, (ii) if practicable, try
all issues of law or fact within one hundred twenty (120) days after the date of the conference and (iii) report a statement of decision within twenty (20) days after the matter has been submitted for decision. 

12.6 The referee will have power to expand or limit the amount and duration of discovery. The referee may set or extend discovery
deadlines or cutoffs for good cause, including a party’s failure to provide requested discovery for any reason whatsoever. Unless otherwise ordered based upon good cause shown, no party shall be entitled to “priority” in conducting
discovery, depositions may be taken by either party upon seven (7) days written notice, and all other discovery shall be responded to within fifteen (15) days after service. All disputes relating to discovery which cannot be resolved by
the parties shall be submitted to the referee whose decision shall be final and binding. 
 12.7 Except as expressly set forth
in this Agreement, the referee shall determine the manner in which the reference proceeding is conducted including the time and place of hearings, the order of presentation of evidence, and all other questions that arise with respect to the course
of the reference proceeding. All proceedings and hearings conducted before the referee, except for trial, shall be conducted without a court reporter, except that when any party so requests, a court reporter will be used at any hearing conducted
before the referee, and the referee will be provided a courtesy copy of the transcript. The party making such a request shall have the obligation to arrange for and pay the court reporter. Subject to the referee’s power to award costs to the
prevailing party, the parties will equally share the cost of the referee and the court reporter at trial. 
 12.8 The referee
shall be required to determine all issues in accordance with existing case law and the statutory laws of the State of California. The rules of evidence applicable to proceedings at law in the State of California will be applicable to the reference
proceeding. The referee shall be empowered to enter equitable as well as legal relief, enter equitable orders that will be binding on the parties and rule on any motion which would be authorized in a court proceeding, including without limitation
motions for summary judgment or summary adjudication. The referee shall issue a decision at the close of the reference proceeding which disposes of all claims of the parties that are the subject of the reference. Pursuant to CCP § 644, such
decision shall be entered by the Court as a judgment or an order in the same manner as if the action had been tried by the Court and any such decision will be final, binding and conclusive. The parties reserve the right to appeal from the final
judgment or order or from any appealable decision or order entered by the referee. The parties reserve the right to findings of fact, conclusions of laws, a written statement of decision, and the right to move for a new trial or a different
judgment, which new trial, if granted, is also to be a reference proceeding under this provision. 
 12.9 If the enabling
legislation which provides for appointment of a referee is repealed (and no successor statute is enacted), any dispute between the parties that would otherwise be determined by reference procedure will be resolved and determined by arbitration. The
arbitration will be conducted by a retired judge or Justice, in accordance with the California Arbitration Act §1280 through §1294.2 of the CCP as amended from time to time. The limitations with respect to discovery set forth above shall
apply to any such arbitration proceeding. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 17	  	May 10, 2013            

 12.10 THE PARTIES RECOGNIZE AND AGREE THAT ALL CONTROVERSIES, DISPUTES AND CLAIMS RESOLVED
UNDER THIS REFERENCE PROVISION WILL BE DECIDED BY A REFEREE AND NOT BY A JURY. AFTER CONSULTING (OR HAVING HAD THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS, HIS OR HER OWN CHOICE, EACH PARTY KNOWINGLY AND VOLUNTARILY, AND FOR THE MUTUAL BENEFIT
OF ALL PARTIES, AGREES THAT THIS REFERENCE PROVISION WILL APPLY TO ANY CONTROVERSY, DISPUTE OR CLAIM BETWEEN OR AMONG THEM ARISING OUT OF OR IN ANY WAY RELATED TO, THIS AGREEMENT OR THE OTHER LOAN DOCUMENTS. 

 

	 	13.	GENERAL PROVISIONS. 

 13.1
Successors and Assigns. This Agreement shall bind and inure to the benefit of the respective successors and permitted assigns of each of the parties and shall bind all persons who become bound as a debtor to this Agreement; provided, however,
that neither this Agreement nor any rights hereunder may be assigned by Borrower without Bank’s prior written consent, which consent may be granted or withheld in Bank’s sole discretion. Bank shall have the right without the consent of or
notice to Borrower to sell, transfer, negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations, rights and benefits hereunder. 
 13.2 Indemnification. Borrower shall defend, indemnify and hold harmless Bank and its officers, employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or
asserted by any other party in connection with the transactions contemplated by this Agreement and/or the Loan Documents; and (b) all losses or Bank Expenses in any way suffered, incurred, or paid by Bank, its officers, employees and agents as
a result of or in any way arising out of, following, or consequential to transactions between Bank and Borrower whether under this Agreement, or otherwise (including without limitation reasonable attorneys fees and expenses), except for losses
caused by Bank’s gross negligence or willful misconduct. 
 13.3 Time of Essence. Time is of the essence for the
performance of all obligations set forth in this Agreement. 
 13.4 Severability of Provisions. Each provision of this
Agreement shall be severable from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision. 
 13.5 Correction of Loan Documents. Bank may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties so long as Bank
provides Borrower with written notice of such correction and allows Borrower at least ten (10) days to object to such correction. In the event of such objection, such correction shall not be made except by an amendment signed by both Bank and
Borrower. 
 13.6 Amendments in Writing, Integration. All amendments to or terminations of this Agreement or the other
Loan Documents must be in writing signed by the parties. All prior agreements, understandings, representations, warranties, and negotiations between the parties hereto with respect to the subject matter of this Agreement and the other Loan
Documents, if any, are merged into this Agreement and the Loan Documents. 
 13.7 Counterparts. This Agreement may be
executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same
Agreement. 
 13.8 Survival. All covenants, representations and warranties made in this Agreement shall continue in full
force and effect until this Agreement is terminated. The obligations of Borrower to indemnify Bank with respect to the expenses, damages, losses, costs and liabilities described in Section 13.2 shall survive until all applicable statute of
limitations periods with respect to actions that may be brought against Bank have run. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 18	  	May 10, 2013            

 13.9 Confidentiality. In handling any confidential information, Bank and all
employees and agents of Bank shall exercise the same degree of care that Bank exercises with respect to its own proprietary information of the same types to maintain the confidentiality of any non-public information thereby received or received
pursuant to this Agreement except that disclosure of such information may be made (i) to the subsidiaries or Affiliates of Bank in connection with their present or prospective business relations with Borrower, (ii) to prospective
transferees or purchasers of any interest in the Loans, (iii) as required by law, regulations, rule or order, subpoena, judicial order or similar order, (iv) as may be required in connection with the examination, audit or similar
investigation of Bank, (v) to Bank’s accountants, auditors and regulators, and (vi) as Bank may determine in connection with the enforcement of any remedies hereunder. Confidential information hereunder shall not include information
that either: (a) is in the public domain or in the knowledge or possession of Bank when disclosed to Bank, or becomes part of the public domain after disclosure to Bank through no fault of Bank; or (b) is disclosed to Bank by a third
party, provided Bank does not have actual knowledge that such third party is prohibited from disclosing such information. 

[remainder of page intentionally left blank] 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 19	  	May 10, 2013            

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date first above written. 
  

			
	REGADO BIOSCIENCES, INC.
		
	By:	 	 /s/ Chris Courts

	Name:	 	 Chris Courts

	Title:	 	 VP Finance

	
	COMERICA BANK
		
	By:	 	 /s/ Jeff Chapman

	Name:	 	 Jeff Chapman

	Title:	 	 SVP

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 20	  	May 10, 2013            

 EXHIBIT A 
 DEFINITIONS 
 “Accounts” means all presently existing and hereafter arising accounts,
contract rights, payment intangibles and all other forms of obligations owing to Borrower arising out of the sale or lease of goods (including, without limitation, the licensing of software and other technology) or the rendering of services by
Borrower and any and all credit insurance, guaranties, and other security therefor, as well as all merchandise returned to or reclaimed by Borrower and Borrower’s Books relating to any of the foregoing. 

“Affiliate” means, with respect to any Person, any Person that owns or controls directly or indirectly such Person, any Person that controls or
is controlled by or is under common control with such Person, and each of such Person’s senior executive officers, directors, and partners. 
 “Bank Expenses” means all reasonable costs or expenses (including reasonable attorneys’ fees and expenses, whether generated in-house or by outside counsel) incurred in connection with the
preparation, negotiation, administration, and enforcement of the Loan Documents; reasonable Collateral audit fees; and Bank’s reasonable attorneys’ fees and expenses (whether generated in-house or by outside counsel) incurred in amending,
enforcing or defending the Loan Documents (including fees and expenses of appeal), incurred before, during and after an Insolvency Proceeding, whether or not suit is brought. 
 “Borrower State” means Delaware, the state under whose laws Borrower is organized. 

“Borrower’s Books” means all of Borrower’s books and records including: ledgers; records concerning Borrower’s assets or
liabilities, the Collateral, business operations or financial condition; and all computer programs, or tape files, and the equipment, containing such information. 
 “Business Day” means any day that is not a Saturday, Sunday, or other day on which banks in the State of California are authorized or required to close. 

“Change in Control” shall mean a transaction in which any “person” or “group” (within the meaning of Section 13(d) and
14(d)(2) of the Securities Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of a sufficient number of shares of all classes of stock then
outstanding of Borrower ordinarily entitled to vote in the election of directors, empowering such “person” or “group” to elect a majority of the Board of Directors of Borrower, who did not have such power before such transaction.

 “Chief Executive Office State” means New Jersey, where Borrower’s chief executive office is located. 

“Clinical Hold” means an order of the FDA suspending the clinical trial of a Product or proposed Product. 

“Closing Date” means the date of this Agreement. 
 “Code” means the California Uniform Commercial Code as amended or supplemented from time to time. 
 “Collateral” means the property described on Exhibit B attached hereto and all Negotiable Collateral to the extent not described on Exhibit B, except to the extent any such
property (i) is nonassignable by its terms without the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406 and
9408 of the Code), (ii) the granting of a security interest therein is contrary to applicable law, provided that upon the cessation of any such restriction or prohibition, such property shall automatically become part of the Collateral, or
(iii) constitutes the capital stock of a controlled foreign corporation (as defined in the IRC), in excess of 65% of the voting power of all classes of capital stock of such controlled foreign corporations entitled to vote. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 1	  	May 10, 2013            

 “Collateral State” means the state or states where the Collateral is located, which is New Jersey.

 “Contested Clinical Hold” means a Clinical Hold, provided that Borrower diligently takes all steps required to terminate said
suspension and said suspension is lifted or otherwise not made permanent. 
 “Contingent Obligation” means, as applied to any Person,
any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including, without limitation, any such obligation directly or
indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit,
corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or
other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for
collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is
made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the
obligations under the guarantee or other support arrangement. 
 “Copyrights” means any and all copyright rights, copyright
applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created,
acquired or held. 
 “Credit Extension” means each Growth Capital Advance or any other extension of credit by Bank to or for the
benefit of Borrower hereunder. 
 “Environmental Laws” means all laws, rules, regulations, orders and the like issued by any federal
state, local foreign or other governmental or quasi-governmental authority or any agency pertaining to the environment or to any hazardous materials or wastes, toxic substances, flammable, explosive or radioactive materials, asbestos or other
similar materials. 
 “Equipment” means all present and future machinery, equipment, tenant improvements, furniture, fixtures,
vehicles, tools, parts and attachments in which Borrower has any interest. 
 “ERISA” means the Employee Retirement Income Security
Act of 1974, as amended, and the regulations thereunder. 
 “Event of Default” has the meaning assigned in Article 8. 

“FDA” means the Food and Drug Administration of the United States of America or any successor entity thereto. 

“Final Payment” is an amount equal to 3.85% of the Growth Capital Advances. 
 “GAAP” means generally accepted accounting principles, consistently applied, as in effect from time to time. 
 “Growth Capital Advance(s)” means a cash advance or cash advances under the Growth Capital Line, including without limitation the Tranche A Growth Capital Advance and the Tranche B Growth
Capital Advance. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 2	  	May 10, 2013            

 “Growth Capital Line” means a Credit Extension of up to Eight Million Five Hundred Thousand
Dollars ($8,500,000). 
 “Growth Capital Maturity Date” means May 10, 2015. 

“Indebtedness” means (a) all indebtedness for borrowed money or the deferred purchase price of property or services, including without
limitation reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, (d) all Contingent
Obligations, and (e) all obligations arising under the Credit Card Services Sublimit, if any. 
 “Insolvency Proceeding” means
any proceeding commenced by or against any Person or entity under any provision of the United States Bankruptcy Code, as amended, or under any other bankruptcy or insolvency law, including assignments for the benefit of creditors, formal or informal
moratoria, compositions, extension generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” means all of Borrower’s right, title, and interest in and to the following: 

 

	(a)	Copyrights, Trademarks and Patents; 

  

	(b)	Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired
or held; 

  

	(c)	Any and all design rights which may be available to Borrower now or hereafter existing, created, acquired or held; 

 

	(d)	Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for
and collect such damages for said use or infringement of the intellectual property rights identified above; 

  

	(e)	All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by
such license or rights; 

  

	(f)	All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and 

 

	(g)	All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the
foregoing. 

 “Inventory” means all present and future inventory in which Borrower has any interest. 

“Investment” means any beneficial ownership of (including stock, partnership or limited liability company interest or other securities) any
Person, or any loan, advance or capital contribution to any Person. 
 “IRC” means the Internal Revenue Code of 1986, as amended, and
the regulations thereunder. 
 “Lien” means any mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance.

 “Loan Documents” means, collectively, this Agreement, any note or notes executed by Borrower, and any other document, instrument or
agreement entered into in connection with this Agreement, all as amended or extended from time to time. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 3	  	May 10, 2013            

 “Material Adverse Effect” means (i) a material adverse change in Borrower’s business or
financial condition, or (ii) a material impairment in the prospect of repayment of all or any portion of the Obligations or in otherwise performing Borrower’s obligations under the Loan Documents, (iii) a material impairment in the
perfection, value or priority of Bank’s security interests in the Collateral. 
 “Negotiable Collateral” means all of
Borrower’s present and future letters of credit of which it is a beneficiary, drafts, instruments (including promissory notes), securities, documents of title, and chattel paper, and Borrower’s Books relating to any of the foregoing.

 “Obligations” means all debt, principal, interest, Bank Expenses and other amounts owed to Bank by Borrower pursuant to this
Agreement or any other agreement, whether absolute or contingent, due or to become due, now existing or hereafter arising, including any interest that accrues after the commencement of an Insolvency Proceeding and including any debt, liability, or
obligation owing from Borrower to others that Bank may have obtained by assignment or otherwise. 
 “Patents” means all patents,
patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same. 
 “Periodic Payments” means all installments or similar recurring payments that Borrower may now or hereafter become obligated to pay to Bank pursuant to the terms and provisions of any
instrument, or agreement now or hereafter in existence between Borrower and Bank. 
 “Permitted Indebtedness” means: 

 

	(a)	Indebtedness of Borrower in favor of Bank arising under this Agreement or any other Loan Document; 

 

	(b)	Indebtedness existing on the Closing Date and disclosed in the Schedule; 

  

	(c)	Indebtedness not to exceed Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate in any fiscal year of Borrower secured by a lien described in clause
(c) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed the lesser of the cost or fair market value of the equipment financed with such Indebtedness; 

 

	(d)	Subordinated Debt; 

  

	(e)	Indebtedness to trade creditors incurred in the ordinary course of business; and 

 

	(f)	Extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose more
burdensome terms upon Borrower or its Subsidiary, as the case may be. 

 “Permitted Investment” means: 

 

	(a)	Investments existing on the Closing Date disclosed in the Schedule; 

  

	(b)	(i) Marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one (1)
year from the date of acquisition thereof, (ii) commercial paper maturing no more than one (1) year from the date of creation thereof and currently having rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or
Moody’s Investors Service, (iii) Bank’s certificates of deposit maturing no more than one (1) year from the date of investment therein, and (iv) Bank’s money market accounts; 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 4	  	May 10, 2013            

	(c)	Repurchases of stock from former employees or directors of Borrower under the terms of applicable repurchase agreements (i) in an aggregate amount not to exceed
One Hundred Thousand Dollars ($100,000) in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases, or (ii) in any amount where the consideration for the repurchase is
the cancellation of indebtedness owed by such former employees to Borrower regardless of whether an Event of Default exists; 

  

	(d)	Investments accepted in connection with Permitted Transfers; 

  

	(e)	Investments of Subsidiaries in or to other Subsidiaries or Borrower and Investments by Borrower in Subsidiaries not to exceed One Hundred Thousand Dollars ($100,000) in
the aggregate in any fiscal year; 

  

	(f)	Investments not to exceed One Hundred Fifty Thousand Dollars ($150,000) in the aggregate in any fiscal year consisting of (i) travel advances and employee
relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee
stock purchase plan agreements approved by Borrower’s Board of Directors; 

  

	(g)	Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent
obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; 

  

	(h)	Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary
course of business, provided that this subparagraph (h) shall not apply to Investments of Borrower in any Subsidiary; and 

  

	(i)	Joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the non-exclusive licensing of technology, the development of
technology or the providing of technical support, provided that any cash Investments by Borrower do not exceed One Hundred Thousand Dollars ($100,000) in the aggregate in any fiscal year. 

“Permitted Liens” means the following: 
  

	(a)	Any Liens existing on the Closing Date and disclosed in the Schedule (excluding Liens to be satisfied with the proceeds of the Growth Capital Advances) or arising under
this Agreement or the other Loan Documents; 

  

	(b)	Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings and for
which Borrower maintains adequate reserves, provided the same have no priority over any of Bank’s security interests; 

  

	(c)	Liens not to exceed Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate (i) upon or in any Equipment (other than Equipment financed by a Growth Capital
Advance) acquired or held by Borrower or any of its Subsidiaries to secure the purchase price of such Equipment or indebtedness incurred solely for the purpose of financing the acquisition or lease of such Equipment, or (ii) existing on such
Equipment at the time of its acquisition, provided that the Lien is confined solely to the property so acquired and improvements thereon, and the proceeds of such Equipment; 

 

	(d)	Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (a) through
(c) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced does not increase; and

  

	(e)	Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Sections 8.5 (attachment) or 8.9 (judgments).

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 5	  	May 10, 2013            

 “Permitted Transfer” means the conveyance, sale, lease, transfer or disposition by Borrower or any
Subsidiary of: 
  

	(a)	Inventory in the ordinary course of business; 

  

	(b)	Non-exclusive licenses and similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary course of business;

  

	(c)	Worn-out or obsolete Equipment not financed with the proceeds of Growth Capital Advances; or 

 

	(d)	Other assets of Borrower or its Subsidiaries that do not in the aggregate exceed One Hundred Thousand Dollars ($100,000) during any fiscal year.

 “Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, trust,
unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or governmental agency. 
 “Prime Rate” means the variable rate of interest, per annum, most recently announced by Bank, as its “prime rate,” whether or not such announced rate is the lowest rate available from
Bank. 
 “Prime Reference Rate Addendum” means that certain Prime Reference Rate Addendum between Borrower and Bank dated as of the
Closing Date. 
 “Product” means Borrower’s REG1 actively controllable anticoagulant targeting Coagulation Factor IXa or any
variant thereof. 
 “Prohibited Territory” means any person or country listed by the Office of Foreign Assets Control of the United
States Department of Treasury as to which transactions between a United States Person and that territory are prohibited. 
 “Responsible
Officer” means each of the Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer and the Controller of Borrower. 
 “Schedule” means the schedule of exceptions attached hereto and approved by Bank, if any. 
 “SOS Reports” means the official reports from the Secretaries of State of each Collateral State, Chief Executive Office State and the Borrower State and other applicable federal, state or local
government offices identifying all current security interests filed in the Collateral and Liens of record as of the date of such report. 

“Subordinated Debt” means any debt incurred by Borrower that is subordinated in writing to the debt owing by Borrower to Bank on terms
reasonably acceptable to Bank (and identified as being such by Borrower and Bank). 
 “Subsidiary” means any corporation, partnership
or limited liability company or joint venture in which (i) any general partnership interest or (ii) more than 50% of the stock, limited liability company interest or joint venture of which by the terms thereof ordinary voting power to
elect the Board of Directors, managers or trustees of the entity, at the time as of which any determination is being made, is owned by Borrower, either directly or through an Affiliate. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 6	  	May 10, 2013            

 “Trademarks” means any trademark and servicemark rights, whether registered or not, applications
to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks. 

  
  

					
	Comerica Bank - Loan and Security Agreement	  	Page 7	  	May 10, 2013            

 Prime Reference Rate Addendum 

To Loan and Security Agreement 
 This Prime Reference Rate Addendum to Loan and Security Agreement (this “Addendum”) is entered into as of May 10, 2013, by and between Comerica Bank (“Bank”) and REGADO
BIOSCIENCES, INC. (“Borrower”). This Addendum supplements the terms of the Loan and Security Agreement dated as of the date hereof (as the same may be amended, modified, supplemented, extended or restated from time to time, the
“Agreement”). 
 1. Definitions. As used in this Addendum, the following terms shall have the following meanings. Initially
capitalized terms used and not defined in this Addendum shall have the meanings ascribed thereto in the Agreement. 
 a.
“Applicable Margin” means four percent (4.0%) per annum. 
 b. “Business Day” means any day, other than
a Saturday, Sunday or any other day designated as a holiday under Federal or applicable State statute or regulation, on which Bank is open for all or substantially all of its domestic and international business (including dealings in foreign
exchange) in San Jose, California, and, in respect of notices and determinations relating the Daily Adjusting LIBOR Rate, also a day on which dealings in dollar deposits are also carried on in the London Interbank market and on which banks are open
for business in London, England. 
 c. “Change in Law” means the occurrence, after the date hereof, of any of the
following: (i) the adoption or introduction of, or any change in any applicable law, treaty, rule or regulation (whether domestic or foreign) now or hereafter in effect and whether or not applicable to Bank on such date, or (ii) any change
in interpretation, administration or implementation thereof of any such law, treaty, rule or regulation by any Governmental Authority, or (iii) the issuance, making or implementation by any Governmental Authority of any interpretation,
administration, request, regulation, guideline, or directive (whether or not having the force of law), including any risk-based capital guidelines. For purposes of this definition, (x) a change in law, treaty, rule, regulation, interpretation,
administration or implementation shall include, without limitation, any change made or which becomes effective on the basis of a law, treaty, rule, regulation, interpretation administration or implementation then in force, the effective date of
which change is delayed by the terms of such law, treaty, rule, regulation, interpretation, administration or implementation, and (y) the Dodd-Frank Wall Street Reform and Consumer Protection Act (Pub. L. 111-203, H.R. 4173) and all
requests, rules, regulations, guidelines, interpretations or directives promulgated thereunder or issued in connection therewith shall be deemed to be a “Change in Law”, regardless of the date enacted, adopted, issued or promulgated,
whether before or after the date hereof, and (z) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the
United States regulatory authorities, in each case pursuant to Basel III, shall each be deemed to be a “Change in Law”, regardless of the date enacted, adopted, issued or implemented. 

d. “Daily Adjusting LIBOR Rate” means, for any day, a per annum interest rate which is equal to the quotient of the following:

  

	 	(1)	for any day, the per annum rate of interest determined on the basis of the rate for deposits in United States Dollars for a period equal to one (1) month appearing
on Page BBAM of the Bloomberg Financial Markets information Service as of 8:00 a.m. (California time) (or as soon thereafter as practical) on such day, or if such day is not a Business Day, on the immediately preceding Business Day. In the event
that such rate does not appear on Page BBAM of the Bloomberg Financial Markets Information Service (or otherwise on such Service) on any day, the “Daily Adjusting LIBOR Rate* for such day shall be determined by reference to such other publicly
available service for displaying eurodollar rates as may be reasonably selected by Bank, or in the absence of such other service, the “Daily Adjusting LIBOR Rate” for such day shall, instead, be determined based upon the average of the
rates at which Bank is offered dollar deposits at or about 8:00 a.m. (California time) (or as soon thereafter as practical), on such day, or if such day is not a Business Day, on the immediately preceding Business Day, in the Interbank eurodollar
market in an amount comparable to the outstanding principal amount of the Obligations and for a period equal to one (1) month; 

 divided by 
  

	 	(2)	1.00 minus the maximum rate (expressed as a decimal) on such day at which Bank is required to maintain reserves on “Euro-currency Liabilities” as defined in
and pursuant to Regulation D of the Board of Governors of the Federal Reserve System or, if such regulation or definition is modified, and as long as Bank is required to maintain reserves against a category of liabilities which includes eurodollar
deposits or includes a category of assets which includes eurodollar loans, the rate at which such reserves are required to be maintained on such category. 

 e. “Governmental Authority” means the government of the United States of America or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority,
instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including, without limitation, any
supranational bodies such as the European Union or the European Central Bank). 

  
 -1-

 f. “LIBOR Lending Office” means Bank’s office located in the Cayman Islands,
British West Indies, or such other branch of Bank, domestic or foreign, as it may hereafter designate as its LIBOR Lending Office by notice to Borrower. 
 g. “Prime Rate” means the per annum interest rate established by Bank as its prime rate for its borrowers, as such rate may vary from time to time, which rate is not necessarily the lowest rate
on loans made by Bank at any such time. 
 h. “Prime Reference Rate” means, for any day, a per annum interest rate
which is equal to the Prime Rate in effect on such day, but in no event and at no time shall the Prime Reference Rate be less than the sum of the Daily Adjusting LIBOR Rate for such day plus two and one-half percent (2.50%) per annum. If, at
any time, Bank determines that it is unable to determine or ascertain the Daily Adjusting LIBOR Rate for any day, the Prime Reference Rate for each such day shall be the Prime Rate in effect at such time, but not less than two and one-half percent
(2.50%) per annum. 
 2. Interest Rate Options. Subject to the terms and conditions of this Addendum, the Obligations under the
Agreement shall bear interest at the Prime Reference Rate plus the Applicable Margin. 
 3. Payment of Interest. Accrued and unpaid
interest on the unpaid balance of the Obligations outstanding under the Agreement shall be payable monthly, in arrears, on the [first Business Day] of each month, until maturity (whether as stated herein, by acceleration, or otherwise). In the event
that any payment under this Addendum becomes due and payable on any day which is not a Business Day, the due date thereof shall be extended to the next succeeding Business Day, and, to the extent applicable, interest shall continue to accrue and be
payable thereon during such extension at the rates set forth in this Addendum. Interest accruing hereunder shall be computed on the basis of a year of 360 days, and shall be assessed for the actual number of days elapsed, and in such computation,
effect shall be given to any change in the applicable interest rate as a result of any change in the Prime Reference Rate on the date of each such change. 
 4. Bank’s Records. The amount and date of each advance under the Agreement, its applicable interest rate, and the amount and date of any repayment shall be noted on Bank’s records, which
records shall be conclusive evidence thereof, absent manifest error; provided, however, any failure by Bank to make any such notation, or any error in any such notation, shall not relieve Borrower of its obligations to repay Bank all
amounts payable by Borrower to Bank under or pursuant to this Addendum and the Agreement, when due in accordance with the terms hereof. 
 5.
Default Interest Rate. From and after the occurrence of any Event of Default, and so long as any such Event of Default remains unremedied or uncured thereafter, the Obligations outstanding under the Agreement shall bear interest at a per
annum rate of five percent (5%) above the otherwise applicable interest rate hereunder, which interest shall be payable upon demand. In addition to the foregoing, a late payment charge equal to five percent (5%) of each late payment
hereunder may be charged on any payment not received by Bank within ten (10) calendar days after the payment due date therefor, but acceptance of payment of any such charge shall not constitute a waiver of any Event of Default under the
Agreement. In no event shall the interest payable under this Addendum and the Agreement at any time exceed the maximum rate permitted by law. 

6. Prepayment. Borrower may prepay all or part of the outstanding balance of any Obligations at any time without premium or penalty. Any
prepayment hereunder shall also be accompanied by the payment of all accrued and unpaid interest on the amount so prepaid. Borrower hereby acknowledges and agrees that the foregoing shall not, in any way whatsoever, limit, restrict, or otherwise
affect Bank’s right to make demand for payment of all or any part of the Obligations under the Agreement due on a demand basis in Bank’s sole and absolute discretion. 
 7. Regulatory Developments or Other Circumstances Relating to the Daily Adjusting LIBOR Rate. 
 a. If any Change in Law shall: (a) subject Bank to any tax, duty or other charge with respect to this Addendum or any Obligations under the Agreement, or shall change the basis of taxation of payments to
Bank of the principal of or interest under this Addendum or any other amounts due under this Addendum in respect thereof (except for changes in the rate of tax on the overall net income of Bank or its LIBOR Lending Office imposed by the jurisdiction
in which Bank’s principal executive office or LIBOR Lending Office is located); or (b) impose, modify or deem applicable any reserve (including, without limitation, any imposed by the Board of Governors of the Federal Reserve System),
special deposit or similar requirement against assets of, deposits with or for the account of, or credit extended by Bank, or shall impose on Bank or the foreign exchange and interbank markets any other condition affecting this Addendum or the
Obligations; and the result of any of the foregoing is to increase the cost to Bank of maintaining any part of the Obligations or to reduce the amount of any sum received or receivable by Bank under this Addendum by an amount deemed by Bank to be
material, then Borrower shall pay to Bank, within fifteen (15) days of Borrower’s receipt of written notice from Bank demanding such compensation, such additional amount or amounts as will compensate Bank for such increased cost or
reduction. A certificate of Bank, prepared in good faith and in reasonable detail by Bank and submitted by Bank to Borrower, setting forth the basis for determining such additional amount or amounts necessary to compensate Bank shall be conclusive
and binding for ail purposes, absent manifest error. 
 b. In the event that any Change in Law affects or would affect the
amount of capital required or expected to be maintained by Bank (or any corporation controlling Bank), and Bank determines that the amount of such capital is increased by or based upon the existence of any obligations of Bank hereunder or the
maintaining of any Obligations, and such increase has the effect of reducing the rate of return on Bank’s (or such controlling corporation’s) capital as a consequence of such obligations or the

  
 -2-

 
maintaining of such Obligations to a level below that which Bank (or such controlling corporation) could have achieved but for such circumstances (taking into consideration its policies with
respect to capital adequacy), then Borrower shall pay to Bank, within fifteen (15) days of Borrower’s receipt of written notice from Bank demanding such compensation, additional amounts as are sufficient to compensate Bank (or such
controlling corporation) for any increase in the amount of capital and reduced rate of return which Bank reasonably determines to be allocable to the existence of any obligations of Bank hereunder or to maintaining any Obligations. A certificate of
Bank as to the amount of such compensation, prepared in good faith and in reasonable detail by Bank and submitted by Bank to Borrower, shall be conclusive and binding for all purposes absent manifest error. 

8. Legal Effect. Except as specifically modified hereby, all of the terms and conditions of the Agreement remain in full force and effect.

 9. Conflicts. As to the matters specifically the subject of this Addendum, in the event of any conflict between this Addendum and the
Agreement, the terms of this Addendum shall control. 
 [signature page follows; remainder of page intentionally left blank]

  
 -3-

 IN WITNESS WHEREOF, the parties have agreed to the foregoing as of the date first set forth
above. 
  

									
	COMERICA BANK	 		 	REGADO BIOSCIENCES, INC.
					
	By:	 	 /s/ Jeff Chapman
	 		 	By:	 	 /s/ Chris Courts

	Name:	 	 Jeff Chapman
	 		 	Name:	 	 Chris Courts

	Title:	 	 SVP
	 		 	Its:	 	 VP Finance

  
 -4-EX-10.47

 Exhibit 10.47 
 CONFIDENTIAL TREATMENT 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN
PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [*], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

CLINICAL DEVELOPMENT AND COLLOBORATION AGREEMENT 

THIS CLINICAL DEVELOPMENT AND COLLABORATION AGREEMENT (the “Agreement”) is made effective as
of the 14th day of May, 2013 (the “Effective
Date”), by and between NovaMedica, LLC (“NovaMedica”), a limited liability company organized under the laws of the Russian federation with an address of 10113 bldg 38, Sokolnichesky Val Street Moscow Russian Federation and
Regado Biosciences, Inc. (“Regado” or “Company”), a corporation organized under the laws of the State of Delaware and having its place of business at 120 Mountain View Boulevard, Basking Ridge New Jersey 07920. For
the purposes of this Agreement, “Party” means NovaMedica and Regado, individually, and “Parties” means NovaMedica and Regado, collectively. 
 WHEREAS, NovaMedica is engaged in the business of the research, development and commercialization of pharmaceutical products in the Territory; and 

WHEREAS, Regado is a development stage company engaged in the research, development and commercialization of certain products
including the Covered Products (as hereinafter defined); and 
 WHEREAS, the Regado and Domain Russia Investments Limited
(“DRI”) entered into a Technology Transfer Agreement (“TTA”) dated December 18, 2012 pursuant to which Regado transferred certain Regado IP (as defined therein) to DRI; and 

WHEREAS, on December 18, 2012, Regado, DRI and NovaMedica entered into an Assignment and Assumption Agreement pursuant to
which DRI assigned the TTA in full to NovaMedica and under which NovaMedica agreed to accept such assignment of rights and to assume all of DRI’s rights and obligations under the TTA; and 

WHEREAS, pursuant to the TTA, the Parties are required to enter into this Agreement; 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth in this Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby, hereby agree as follows. 

1. DEFINITIONS 

“Blocking Third Party Intellectual Property” shall mean on a country-by-country basis, a valid patent or patent application in the
Territory owned or otherwise controlled by a Third Party, in the absence of a license to which, the Development and/or Commercialization of Compound or a Covered Product would infringe such patent or a patent that issues from such patent

 
application and will prevent NovaMedica and/or Permitted Transferees to Develop, Commercialize, obtain Regulatory Approval of the Covered Products in any country within the Territory. 

“Affiliate” shall mean, in relation to any Party or Permitted Transferee, any Person who directly or indirectly controls, is controlled
by, or is under common control with, such Party or Permitted Transferee. For purposes of this definition of Affiliate, “control” means: (a) ownership of more than fifty percent (50%) of the voting rights, shares or other equity
interest of the applicable entity; and/or (b) the power to direct or cause direction of all aspects of the management and policies of the applicable entity (directly or indirectly, whether through ownership of securities or partnership or other
ownership interests, by contract or otherwise). Notwithstanding the foregoing, neither DRI nor RMI Investments S.à r.l. (“RMI”) shall be deemed to be an Affiliate of NovaMedica unless otherwise expressly indicated in the
applicable provision of the Agreement. 
 “Clinical Data” shall have the meaning set forth in Section 3.3.2.

 “Clinical Supply” shall mean supply of the Covered Products in suitable form, whether manufactured by Regado or Company
Manufacturer, manufactured in compliance with GMP, if required given the intended use, and ready to be used for the conduct of pre-clinical and/or Clinical Trials of the Covered Products in the Field by NovaMedica. 

“Clinical Trial” means a clinical trial, investigation, or study in human subjects that has been approved by a Regulatory Authority and
is designed to measure the safety and/or efficacy of a Covered Product in humans. 
 “Compound” means any of the following
pharmaceutical compounds, the chemical structures of which are described in Schedule 1.5 hereto, in any formulation: (i) pegnivacogin (RB006), (ii) anivamersen (RB007), (iii) RB571 and (iv) RB515. Additionally, Compound means
(A) subject matter disclosed in patent applications relating to (i) CLEC-2; (ii) Alpha2Beta1 I-domain; (iii) GAS6; (iv) analysis, manufacture and formulation of pegylated oligonucleotides; and (B) any and all other
compounds which, as of the Effective Date, are either (i) under development by Regado or (ii) planned to be developed by Regado after the Effective Date pursuant to the current development program(s) of Regado. 

“Commercially Significant Indications” shall have the meaning set forth in Section 3.1. 

“Commercial Supplies” shall mean supplies of the Covered Products in suitable final packaged form, as specified under the Commercial
Supply Agreement to be executed by the Parties, manufactured in compliance with GMP, and ready to be offered for commercial sale for use in the Field in the Territory by NovaMedica and/or Permitted Transferees. 

“Confidential Information” of a Party means such Party’s confidential information relating to its business, operations and
products, including but not limited to, any technical information, formulae, processes, techniques, preclinical information, toxicology information, clinical, non-clinical, or pre-clinical information, regulatory information, Manufacturing
information, formulation information, packaging information, dosing information, dose regimen information, target patient information, marketing information, sales information, pricing information,

  
 -2-

 
reimbursement information, Know-How, trade secrets, or inventions (whether patentable or not) that is disclosed to or learned by the other Party in connection with this Agreement. All non-public
Regado Know-How shall be deemed Confidential Information of Regado and all Arising Know How shall be deemed Confidential Information. 

“Covered Product” means any pharmaceutical product (including, without limitation, any diagnostic product) containing or comprising any
Compound in any formulation designed and intended for use in and for the Field, whether or not combined with other compounds. 

“Development” or “Develop” means the performance of all development activities, including any research, non-clinical,
pre-clinical and clinical development activities (including, without limitation, toxicology, pharmacology, test method development and stability testing, process development, formulation development, quality control development, statistical
analysis, Clinical Trials, and manufacturing and regulatory activities or any similar activities) that are useful or otherwise required to obtain Regulatory Approval of a Covered Product in the Territory, including interacting with any Regulatory
Authorities regarding the foregoing. 
 “Development Plan” shall have the meaning set forth in Section 3.1.

 “Drug Approval Application” shall mean an application to a Regulatory Authority in the Territory for Regulatory Approval of
a Covered Product. 
 “EMA” means the European Medicines Agency or any successor agency. 

“FDA” shall mean the United States Food and Drug Administration and any successor agency performing similar functions. 

“Field” means any and all prophylactic, palliative, therapeutic, and diagnostic uses for any human or animal disease or condition.

 “First Commercial Sale” shall mean the first sale in the Territory of a Covered Product by NovaMedica (or a Permitted
Transferee) to an unaffiliated third party in a bone fide arm’s length transaction. 
 “Global Clinical Trial Program”
shall mean Regado’s pivotal Phase 3 Clinical Trial for REG1 known as Regulate-PCI. 
 “IND” means an investigational new
drug application filed with the FDA or the equivalent application or filing filed with any equivalent agency or Regulatory Authority outside the United States (including any supra-national entity such as in the European Union) for approval to
commence Clinical Trials in such jurisdiction. 
 “Indication” means a generally acknowledged disease or condition, a
significant manifestation of a disease or condition, or symptoms associated with a disease or condition or a risk for a disease or condition. For the avoidance of doubt, all variants of a single disease or condition (whether classified by severity
or otherwise) shall be treated as the same Indication. 
 “Joint Commercialization Committee” or “JCC” has the
meaning given in Section 3.3, below. 

  
 -3-

 “Joint Development Committee” or “JDC” has the meaning given in
Section 3.2, below. 
 “Joint Invention” shall mean any discovery, invention, innovation or other technical
advance, whether or not patentable, jointly conceived or discovered by at least one Person who is an employee, officer, director, agent or contractor of Regado and at least one Person who is an employee, officer, director, agent or contractor of
NovaMedica or a Permitted Transferee. 
 “Joint Steering Committee” or “JSC” has the meaning given in
Section 3.1, below. 
 “Law” or “Laws” means all applicable laws, statutes, rules, regulations,
ordinances, and other pronouncements having the binding effect of law of any Governmental Body. 
 “NDA” means a New Drug
Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR.§ 314.3, et seq, a Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR § 601, and any
equivalent application filed (i) in any country outside of the Territory by or on behalf Regado or its successor or licensee or (ii) in any country within the Territory by or on behalf of NovaMedica or its successor or a Permitted
Transferee, together, in each case, with all additions, deletions or supplements thereto. 
 “NDA Acceptance” means the receipt
of notice from the relevant Regulatory Authority that an NDA for the Covered Product has met all the criteria for filing acceptance. 

“Permitted Transferee” means an assignee, licensee or sublicensee of NovaMedica of any of the rights and licenses assigned to NovaMedica
under the TTA and this Agreement. 
 “Priority Application” shall have the meaning set forth Section .5.1. 

“Product Trademark” shall have the meaning set forth in Section 5.1. 
 “REG1” shall mean an intravenous bolus injection of pegnivacogin and anivamersen. 

“Regulatory Authority” means (a) the FDA, (b) the EMA or the European Commission, (c) any successor or equivalent of the
foregoing; or (d) any regulatory body with regulatory authority or oversight over pharmaceutical or biotechnology products in the Territory or (e) any regulatory body with regulatory authority or oversight over pharmaceutical or
biotechnology products in any other jurisdiction anywhere in the world, or whose review or approval is necessary for exercise of any rights granted hereunder. 
 “Regulatory Approval” means, with respect to a particular Covered Product, any and all approvals, licenses, registrations, or authorizations of a relevant Regulatory Authority (including
Price Approvals) necessary for the Development, Manufacture, and/or Commercialization of such Covered Product in a particular country or jurisdiction. For the avoidance of doubt, Regulatory Approval in the United States shall be deemed to occur upon
approval of the applicable NDA (as defined above) in the United States, and shall not be construed to require a determination or approval of reimbursements of any type. 
 “Supplemental Development Plan” shall have the meaning set forth in Section 3.1.4. 

  
 -4-

 “Territory” means all countries listed in Schedule 1.26 hereto. 

“Third Party” means any Person other than Regado, or NovaMedica, or an Affiliate of either Regado, or NovaMedica. 

“Third Party Agreements” shall have the meaning set forth in Section 3.7.1. 

Interpretation. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or
interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections, or Schedules mean the particular Articles, Sections, or Schedules to this Agreement and references to this Agreement include
all Schedules hereto. Unless context otherwise clearly requires, whenever used in this Agreement: (i) “include” or “including” shall be construed as if followed by the words “but not limited to” or “without
limitation” or words of similar import; (ii) the word “or” shall be construed as the inclusive meaning identified with the phrase “and/or;” (iii) provisions that require that a Party, the Parties,
“agree,” “consent” or “approve” or the like shall require that such agreement, consent, or approval be specific and in writing, whether by written agreement, letter, written approval of minutes or otherwise; and
(iv) references to any specific Law or article, section, or other division thereof shall be deemed to include then-current amendments thereto or any replacement Law thereof. This Agreement was prepared in the English language, which language
shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. In the event any term or provision of this Agreement conflicts with the terms of the TTA, the terms of the TTA shall control. 

In this Agreement, unless the context requires otherwise: 
 (a) the headings are included for convenience only and shall not affect the construction of this Agreement; 
 (b) words denoting the singular shall include the plural and vice versa; 
 (c)
words denoting one gender shall include each gender and all genders; 
 (d) the words “include” or
“including” shall mean “include, without limitation” or “including, without limitation,” as the case may be, and the language following “include” or “including” shall not be deemed to set forth an
exhaustive list; and 
 (e) any reference to an enactment or statutory provision is a reference to it as it may have been, or
may from time to time be amended, modified, consolidated or reenacted. 
 (f) any Capitalized Terms not specifically defined
herein shall have the meaning set forth in the TTA. 
 The Schedules to this Agreement comprise part of and shall be construed in accordance
with the terms of this Agreement. 

  
 -5-

 2. SCOPE AND MANAGEMENT OF COLLABORATION 

2.1 Collaboration Goals. Consistent with the TTA and subject to the terms and conditions set forth herein, Regado agrees to
assist NovaMedica in the Development and Commercialization of Covered Products in the Territory. Notwithstanding anything in this Agreement to the contrary, either Party shall be free to work alone or with Third Parties to research, develop,
manufacture and/or commercialize any product that is not a Covered Product in or outside the Field. 
 2.2 Joint
Steering Committee. 
 2.2.1 Within thirty (30) days of the Effective Date, the Parties shall establish a Joint
Steering Committee (“JSC”) to oversee Development of Covered Products unless sooner terminated by consent of the Parties shall remain in existence until the later of (i) one (1) year following the First Commercial Sale of
a Covered Product in the Territory or (ii) three (3) years following receipt of Regulatory Approval of a Covered Product in the Territory. The JSC will be comprised of an equal number of members appointed by NovaMedica and Regado. The JSC
shall oversee the Development of Covered Products in the Field in the Territory consistent with the Development Plan, as described in Section 4, below. All JSC decisions will be made by unanimous vote, with the JSC representatives of Regado
collectively having one vote and the JSC representatives of NovaMedica collectively having one vote. If the JSC is unable to decide or resolve unanimously any matter properly presented to it for action, then such matter shall be resolved as provided
in Section 3.1.3 below. 
 2.2.2 Chairmanship. One JSC representative from a Party shall chair the JSC (the
“Chairperson”) on a rotating annual calendar year basis, alternating between a representative from NovaMedica and a representative from Regado, with the initial Chairperson to be from NovaMedica. The Chairperson shall send notices
and agendas for all JSC meetings to all JSC members and ensure review and approval of the minutes of each JSC meeting within thirty (30) calendar days of adjournment of a JSC meeting. 

2.2.3 Meetings. Unless otherwise agreed in writing by NovaMedica and Regado, the JSC will meet as needed upon request from
at least one of the Parties to the then-current Chairperson, but not less than twice per year. At each meeting, the Parties shall provide updates on the status of their respective responsibilities. Meetings may be held by teleconference,
videoconference or in person, as mutually agreed upon by the Parties. At each meeting, a secretary shall by appointed by the Chairperson to record meeting minutes. Within ten (10) calendar days after a meeting, the Chairperson shall circulate
draft minutes to the Parties for review, comment and distribution, in order to finalize the minutes within thirty (30) calendar days of such meeting. 
 2.2.4 Dispute Resolution. If a dispute arises in connection with the Development Plan, Commercialization of the Covered Product or any other issue addressed by the JSC, the JSC shall confer
immediately and use commercially reasonable efforts to resolve the dispute or issue within ten (10) calendar days of their initial conference. No such dispute or issue shall be considered resolved until the JSC has unanimously agreed to the
resolution; provided, however, that if the JSC does not reach consensus, within a thirty (30) calendar day 

  
 -6-

 
period, the resolution of the dispute or issue if it relates to Development shall be made by the JSC representatives of Regado or if it relates to Commercialization in the Territory shall be made
by the JSC Representative of NovaMedica unless such resolution in the opinion of any member of the JSC would be reasonably expected to be adverse to, materially conflict with, or interfere with the regulatory approval, manufacture, marketing
authorization or marketing efforts for Covered Products outside of the Territory (in the case of Regado) or inside the Territory (in the case of NovaMedica), in which case such dispute will be handled in accordance with Section 8 of this
Agreement. 
 2.3 Joint Development Committee. 

2.3.1 Within thirty (30) days of the Effective Date, the Parties shall establish a Joint Development Committee
(“JDC”) which unless sooner terminated by consent of the Parties shall remain in existence until the later of (i) one (1) year following the First Commercial Sale of a Covered Product in the Territory or (ii) three
(3) years following receipt of Regulatory Approval of a Covered Product in the Territory. All day-to-day Development work shall be conducted under the direction of the JDC which shall be comprised of an equal number of representatives from
NovaMedica and Regado. All JDC decisions will be made by unanimous vote. The JDC will be responsible for drafting the Development Plan for submission to the JSC, coordinating amendments to any Development Plan in respect of a Covered Product for use
in the Field in the Territory, for overseeing such Development work, and for making operational decisions related to such Development work. 
 2.3.2 Chairmanship. One JDC representative from a Party shall chair the JDC (the “Chairperson”) on a rotating annual calendar year basis, alternating between a
representative from NovaMedica and a representative from Regado, with the initial Chairperson to be from NovaMedica. The Chairperson shall send notices and agendas for all JDC meetings to all JDC members and ensure review and approval of the minutes
of each JDC meeting within thirty (30) calendar days of adjournment of a JSC meeting. 
 2.3.3 Meetings. The
JDC will meet as needed upon request from at least one of the Parties to the then-current Chairperson, but not less than once every calendar quarter. At each meeting, the Parties shall provide updates on the status of their respective
responsibilities. Meetings may be held by teleconference, videoconference or in person, as mutually agreed upon by the Parties. At each meeting, a secretary shall by appointed by the Chairperson to record meeting minutes. Within ten
(10) calendar days after a meeting, the Chairperson shall circulate draft minutes to the Parties for review, comment and distribution, in order to finalize the minutes within thirty (30) calendar days of such meeting. 

2.3.4 Dispute Resolution. If a dispute arises in connection with the Development Plan or Development of the Covered
Products or any other issue addressed by the JDC, the JDC shall confer immediately and use commercially reasonable efforts to resolve the dispute or issue within ten (10) calendar days of their initial conference. No such dispute or issue shall
be considered resolved until the JDC has unanimously agreed to the resolution; provided, however, that if the JDC does not reach consensus, within a thirty (30) calendar day period, the resolution of the dispute or issue shall be made by the
JDC representatives of Regado unless such resolution in the opinion of any member of the JDC would be reasonably 

  
 -7-

 
expected to be adverse to, materially conflict with the Development or regulatory approval for Covered Products in the Territory, in which case such dispute will be handled in accordance with
Section 11 of this Agreement. 
 2.4 Joint Commercialization Committee. 

2.4.1 Within thirty (30) days after the Effective Date, the Parties shall establish a Joint Commercialization Committee
(“JCC”) which unless sooner terminated by consent of the Parties shall remain in existence until the later of (i) one (1) year following the First Commercial Sale of a Covered Product in the Territory or (ii) three
(3) years following receipt of Regulatory Approval of a Covered Product in the Territory. The day-to-day Commercialization preparation work and supply chain audit procedures shall be conducted under the direction of the JCC. The JCC shall be
comprised of an equal number of representatives from NovaMedica and Regado. All JCC decisions will be made by unanimous vote. Prior to the First Commercial Sale of a Covered Product (or such longer period as the Parties may agree in writing), the
JCC will be responsible for coordinating any amendments to the plan for Commercialization of Covered Product(s) in the Territory, for overseeing performance of the Commercialization program, for determining patent strategy relative to Joint
Inventions and for making operational decisions related to that program. Periodically, a member of the JCC for each party shall provide to the other party a reasonably detailed summary of the Commercialization activities conducted in the Territory.
The JCC will jointly prepare and provide to each Party on at least a Calendar Quarter basis a report, via e-mail, regarding the status of Commercialization activities hereunder. 

2.4.2 Chairmanship. One JCC representative from a Party shall chair the JCC (the “Chairperson”) on a
rotating annual calendar year basis, alternating between a representative from NovaMedica and a representative from Regado, with the initial Chairperson to be from NovaMedica. The Chairperson shall send notices and agendas for all JCC meetings to
all JCC members and ensure review and approval of the minutes of each JCC meeting within thirty (30) calendar days of adjournment of a JSC meeting. 
 2.4.3 Meetings. The JCC will meet as needed upon request from at least one of the Parties to the then-current Chairperson, but not less than once every calendar quarter. At each meeting, the
Parties shall provide updates on the status of their respective responsibilities. Meetings may be held by teleconference, videoconference or in person, as mutually agreed upon by the Parties. At each meeting, a secretary shall by appointed by the
Chairperson to record meeting minutes. Within ten (10) calendar days after a meeting, the Chairperson shall circulate draft minutes to the Parties for review, comment and distribution, in order to finalize the minutes within thirty
(30) calendar days of such meeting. 
 2.4.4 Dispute Resolution. If a dispute arises in connection with the
Commercialization of the Covered Products or any other issue addressed by the JCC, the JCC shall confer immediately and use commercially reasonable efforts to resolve the dispute or issue within ten (10) calendar days of their initial
conference. No such dispute or issue shall be considered resolved until the JCC has unanimously agreed to the resolution; provided, however, that if the JCC does not reach consensus, within a thirty (30) calendar day period, the resolution of
the dispute or issue shall be made by the JCC representatives of NovaMedica unless such 

  
 -8-

 
resolution in the opinion of any member of the JSC would be reasonably expected to be adverse to, materially conflict with, or interfere with the regulatory approval, manufacture, marketing
authorization or marketing efforts for Covered Products outside of the Territory, in which case such dispute will be handled in accordance with Section 11 of this Agreement. 

3. DEVELOPMENT 
 3.1 Development Plan. 
 3.1.1 Consistent with the TTA, a
plan (the “Development Plan”) to obtain Regulatory Approval for REG1 in the Territory for an Indication with significant commercial potential (“Commercially Significant Indications”) as determined by the JSC shall be prepared by
the JDC within ninety (90) days of the Effective Date or such other time agreed by the JSC. The Parties agree to cooperate with each other in carrying out the Development Plan consistent with the obligations set forth in Sections 3.2 and 3.3
hereof. Development activities will to the extent practicable, utilize the then-prevailing development infrastructure and expertise of each Party in a given activity or with respect to a specific Commercially Significant Indication. 

3.1.2 Except as expressly specified herein, NovaMedica shall not be obliged to reimburse Regado for any costs and expenses
incurred by Regado in connection with any studies, research and Development conducted by or on behalf of Regado outside and inside the Territory necessary for Regado to obtain Regulatory Approval for a Covered Product in any country outside the
Territory. 
 3.1.3 Reserved. 
 3.1.4 Supplemental Development Plans. The JDC shall prepare one or more additional plans to obtain Regulatory Approval for REG1 for one or more additional Commercially Significant
Indications in the Territory or for a Covered Product other than REG1 for one or more Commercially Significant Indications in the Territory, as determined by the JDC (“the Supplemental Development Plan” or “Supplemental
Development Plans”). 
 3.1.5 Regado shall keep the JDC reasonably informed about the status of Regado’s
Global Clinical Trial Program outside of the Territory and provide a list of sites being utilized for the Global Clinical Trial Program in the Territory. 
 3.2 Responsibilities of NovaMedica. With coordination of the JSC, JDC or JCC, if applicable and consistent with the Development Plan and any Supplemental Development Plan, NovaMedica shall:

 3.2.1 at its sole cost and expense and using Commercially Reasonable Efforts, be responsible for implementation of
the Development Plan and any Supplemental Development Plan approved by the JSC; 
 3.2.2 be responsible for the
preparation and filing at its sole cost and expense of any applications to register or obtain the Regulatory Approvals for REG1, any of the other Covered Products and/or Compound in the Territory; 

  
 -9-

 3.2.3 be responsible at its sole cost and expense for the performance of all
activities and undertakings as may be required by any Regulatory Authorities to register or obtain the Regulatory Approval in the Territory of REG1 or any of the Covered Products; 

3.2.4 at its sole cost and expense, be responsible for the Commercialization of the Covered Products, including all sales and
marketing activities, in the Field in the Territory; 
 3.2.5 following receipt of Regulatory Approval, be responsible
at its sole cost and expense for the maintenance and updating of all Regulatory Approvals as may be required by any Regulatory Authorities, including any post approval studies required by any Regulatory Authorities and pharmacovigilance; 

3.2.6 perform such other obligations contemplated by this Agreement and the TTA; 

3.2.7 in cases specified in the TTA and in this Agreement, reimburse Regado all Out-of-Pocket expenses incurred by Regado in
performing its obligations hereunder; and 
 3.2.8 such other activities requested by the JSC, JDC or JCC. 

3.3 Responsibilities of Regado. Under the supervision of each of the JSC, JDC or JCC and consistent with the Development
Plan and any Supplemental Development Plan, Regado shall: 
 3.3.1 Make available to NovaMedica (subject to any
confidentiality obligations to Third Parties) copies of any and all documentation in possession of Regado related to the Covered Products and/or Compound including but not limited to research data and reports, regulatory materials and correspondence
(including INDs and NDAs in U.S.), clinical and preclinical data (including all raw data), chemistry, manufacturing and controls (CMC) data, relevant to conducting clinical studies and obtaining Regulatory Approval in the Field in the Territory
(collectively, the “Clinical Data”) and NovaMedica shall have the right to use the Clinical Data solely in connection with, and as necessary for, the Development and Commercialization of the Covered Products and/or Compound in the
Territory. Except as provided herein, NovaMedica and any Permitted Transferee shall be entitled at no cost to access, use, and reference the data and results from any Regado Clinical Trial of a Covered Product and/or Compound in any Indication for
their own Regulatory Approval, Development, and Commercialization purposes in the Field in the Territory; provided however that in no event shall NovaMedica (or any Permitted Assignee) transfer or make the Clinical Data available to a Third Party
without the express written consent of Regado; 
 3.3.2 upon NovaMedica’s request and subject to any limitations
contained in this Agreement transfer Company Materials to NovaMedica; 
 3.3.3 make available its personnel that are
knowledgeable of the Covered Product (or any constituent Compound) and its properties and functions to provide scientific and technical explanations, advice, and on-site support, that may reasonably be

  
 -10-

 
required by NovaMedica, relating to the Development and Commercialization of the Covered Product and/or Compound (the foregoing activities being referred to as “Development Support”).
NovaMedica shall reimburse Regado for Regado’s documented Out of Pocket Expenses incurred in providing Development Support hereunder. 
 3.3.4 Subject to and in accordance with the Development Plan assist NovaMedica to conduct all relevant Clinical Trials, non-clinical and preclinical studies and research and other Development
activity; 
 3.3.5 provide (and shall make Commercially Reasonable Efforts to require any other Regado Affiliate,
successor, or licensee outside of the Territory to provide) reasonable assistance to NovaMedica (and NovaMedica shall reimburse for Out-of-Pocket Expenses) in the preparation of and filing of any IND, IND amendment, or Drug Approval Application with
respect to any Covered Product in the Territory. Such assistance shall include, in particular, Company (or its Affiliate, successor, or licensee outside of the Territory) providing NovaMedica, to the extent an electronic copy is available or in
possession of Company, with a complete electronic copy of all relevant documentation submitted to the FDA or EMA in respect of any Clinical Trial for any Covered Product that would be necessary or useful to NovaMedica in preparing its own IND for a
particular Covered Product for use in the Territory, and, to the extent necessary or useful, to allow NovaMedica to cross-reference any such IND, IND amendment, or NDA held by Company (or its Affiliate, successor, or licensee outside of the
Territory); 
 3.3.6 make Commercially Reasonable Efforts to include sites in the Russian Federation in any of its other
global Clinical Trials for the Covered Products; 
 3.3.7 make available (subject to any obligations of confidentiality
to Third Parties) to NovaMedica copies of any and all documents in possession of Regado related to the Commercialization of the Covered Products outside of the Territory including any marketing, promotional or other materials related to the Covered
Products; 
 3.3.8 until the First Commercial Sale of a Covered Product within the Territory, NovaMedica or its
Affiliates or Permitted Transferees shall have the right to purchase such reasonable quantities of Compounds and/or Covered Product from Regado (or purchase the right for delivery of Clinical Trials supplies so ordered from a Third Party contract
manufacturer) as are reasonable and necessary to conduct Clinical Trials of Covered Product in the Territory; provided that any such purchase does not reasonably interfere with Regado having sufficient supplies of Compounds and/or Covered Products
on hand for use in Development (including the conduct of Clinical Trials) or Commercialization outside of the Territory. Such purchases will be made from Company on a [*] basis. Unless extended by the JSC, the Parties shall enter into a Clinical
Supply Agreement within one hundred twenty (120) days of the Effective Date in a form and substance to be mutually agreed upon by the Parties. The Clinical Supply Agreement shall set forth in reasonable detail the methodology for determining
Regado’s cost of goods to be supplied to NovaMedica under the Clinical Supply Agreement; and 

  
 -11-

 3.3.9 execute such other agreements (including the Pharmacovigilance Agreement
described in Section 4.3 of the TTA) and perform such other obligations contemplated by the TTA. 
 3.4 Drug
Approval Applications. NovaMedica shall be entitled to file Drug Approval Applications and seek Regulatory Approvals for the Covered Products in the Territory, provided that such filing shall be subject to the oversight of the JDC. Prior to
submitting any IND or Drug Approval Application, the Parties, through the JDC, shall consult and cooperate in preparing such filings, their content and scope. NovaMedica shall own all regulatory submissions, including all INDS, Drug Approval
Applications and associated government licenses, approvals, and certificates for the Covered Products and/or Compound in the Territory. 
 3.5 Clinical Trials in the Territory. Regado will conduct at its own costs Clinical Trials in the Territory as part of its Global Clinical Trial Program. NovaMedica shall have the right to
conduct at its own costs additional Clinical Trials in the Territory which are necessary to obtain Regulatory Approval in each country in the Territory. All clinical data and reports related to Clinical Trials conducted by NovaMedica for the Covered
Products in the Territory shall be owned by NovaMedica, and NovaMedica shall have full use, for any purpose consistent with this Agreement, of all such data and reports related to Clinical Trials for the Covered Products and/or Compound. NovaMedica
shall provide Regado with all such clinical data and reports for Regado’s use, for any purpose consistent with this Agreement and TTA outside of the Territory. All clinical data and reports related to Clinical Trials conducted by Regado for the
Covered Products in the Territory shall be owned by Regado, and Regado shall provide NovaMedica with all such clinical data and reports for NovaMedica’s use, for any purpose consistent with this Agreement and the TTA and of all such data and
reports related to Clinical Trials for the Covered Products in the Territory. 
 3.6 Regulatory Meetings and
Communications. 
 3.6.1 Upon decision of the JSC and NovaMedica’s reasonable request Regado will participate
in substantive discussions and meetings with Regulatory Authorities in the Territory which relate to the Covered Products and/or Compound, including, but not limited to, with respect to any Drug Approval Applications. 

3.6.2 The JDC shall develop processes and procedures for the conduct and reporting to the Parties of telephone communications and
written correspondence with Regulatory Authorities in the Territory related to the Covered Products and/or Compound. 

3.6.3 Within sixty (60) days after the Effective Date, the Parties’ respective regulatory affairs or other applicable
departments, including the members of the JDC with regulatory and drug safety expertise, shall meet and agree upon processes and procedures to recommend to the JDC for sharing information needed to support each Party’s respective regulatory
responsibilities, including without limitation, development of appropriate safety databases relating to Covered Products and/or Compound. The processes and procedures adopted by the JDC under this Section for sharing of information and adverse event
reporting shall be consistent with Section 6. 

  
 -12-

 3.6.4 The Parties shall cooperate in good faith with respect to the conduct of any
scheduled inspections by any Regulatory Authority of a Party’s site and facilities related to the Covered Products and/or Compound, and each Party shall to the extent practicable be given the opportunity to attend the summary, or wrap up,
meeting related to the Covered Products and/or Compound with such Regulatory Authority at the conclusion of such site inspection. 
 3.7 Third Party Agreements. 
 3.7.1 Regado acknowledges
that, as of the Effective Date, Regado has certain existing material transfer agreements and collaboration agreements involving use of the Covered Products and/or Compound (“Third Party Non-IP Agreements”) and certain Third Party Licenses
(collectively, “Third Party Agreements”). The full list of the Third Party Agreements is provided in Schedule 3.7.1 to this Agreement. 
 3.7.2 Third Party IP Agreements. Consistent with the responsibilities set forth in this Agreement, and with the consent of the appropriate Third Party, if required, Regado agrees promptly to
provide NovaMedica with all data, reports and information Regado receives under such Third Party Non-IP Agreements related to the Development Plan and any Supplemental Development Plan. Regado shall notify the JSC of any material transfer agreement
or collaboration agreement involving the use of the Covered Products and/or Compound to be executed after the Effective Date or any amendments or extensions of any Third Party Non-IP Agreement, and shall act in good faith to conserve the available
quantities of the Company Materials and the Covered Product consistent with Regado’s responsibilities under this Agreement or the TTA. 
 3.7.3 Third Party Licenses. Consistent with the TTA, Regado shall, upon the written notice of NovaMedica, use Commercially Reasonable Efforts to obtain any consents or approvals necessary to
obtain Control of Third Party IP (if any) pursuant to the existing Third Party Licenses or any new Third Party License in the Territory. If Regado obtains such Control (or otherwise has Control), Regado shall promptly notify NovaMedica, to that
effect, and shall grant NovaMedica a sublicense in accordance with the TTA. 
 3.7.4 Other Licenses. If either
Party becomes aware of Blocking Third Party Intellectual Property, it shall notify the JSC. If the Blocking Third Party Intellectual Property has no foreign equivalents, NovaMedica shall determine whether, on what terms (economic or otherwise) such
Blocking Third Party Intellectual Property, shall be licensed by NovaMedica for the purposes of this Agreement and the TTA. If the Blocking Third Party Intellectual Property has equivalent patents or patent applications outside of the Territory
(“Foreign Equivalents”) owned or otherwise controlled by the Third Party, Regado shall determine if the Foreign Equivalents are necessary or useful to Development or Commercialization of a Compound or Covered Product outside of the
Territory. If Regado’s determination is affirmative, the JSC will determine whether, on what terms (economic or otherwise) such Blocking Third Party Intellectual Property shall be licensed by NovaMedica. For clarity, NovaMedica shall not enter
into any license to the Foreign Equivalents without Regado’s consent and only then, with a sublicense right on terms approved by the JSC. 

  
 -13-

 4. COMMERCIALIZATION 

4.1 Product Trademarks. The Covered Products shall be sold in the Territory under the Regado Trademarks or NovaMedica
Trademarks as selected by NovaMedica (the “Product Trademarks”). The term “Product Trademarks” shall also include any service marks for use in connection with services related to the Covered Products. In the event of a
Third Party challenge of the Parties right to commercialize the Covered Products under Product Trademarks, the JSC shall consider the grounds for such challenge and recommend to the JCC a course of action in the affected market based on an
assessment of the legal merits of such Third Party claim. The foregoing procedure shall also be followed in the event of an objection to the Regado Trademarks raised by a Regulatory Authority that is reviewing a Drug Approval Application.

 4.2 Sales Representative Training. NovaMedica shall supervise and maintain such competent and qualified sales
representatives. With respect to each country in the Territory, the sales representatives of NovaMedica shall be trained by NovaMedica with reasonable assistance of Regado. Regado shall periodically provide materials (at NovaMedica’s cost and
expense) for training, in accordance with the training requirements and training programs approved by the JCC. NovaMedica shall in all material respects conform their practices and procedures relating to promotion to the applicable laws, rules and
regulations in the Territory. Each Party shall cause each of its employees, representatives and agents, including, without limitation, each of its Sales Representatives, to do nothing which such Party knows or reasonably should know would jeopardize
the goodwill or reputation of either Party or the Covered Products. 
 4.3 Commercial Supplies. Within ninety
(90) days of Regulatory Approval in the United States for REG1 (or such other Covered Product), the Parties will enter into a Commercial Supply Agreement in a form and on terms to be mutually agreed upon by the Parties. The Commercial Supply
Agreement shall set forth in reasonable detail the methodology for determining Regado’s cost of goods to be supplied to NovaMedica under the Commercial Supply Agreement. 
 4.4 Recalls. Decisions with respect to recalls, withdrawals or corrections of the Covered Products in the Territory related to manufacturing or product quality issues shall be handled in
accordance with the Commercial Supply Agreement. The JCC shall have decision-making authority with respect to issuing all recall, market withdrawal or correction of any the Covered Products in the Territory related to safety issues. Each Party shall
delegate their appropriate executive officers in their respective regulatory departments who shall develop appropriate standard operating procedures with respect to such recalls. To the extent regulatory timeframes or public safety considerations
require immediate action, a telephone conference of the JCC’s designees under this Section shall be called within the required timeframe to consider the action and make a decision. Each Party shall notify the other Party promptly (and in any
event within twenty-four (24) hours of receipt of written notice) if the Covered Product is alleged or proven to be the subject of a recall, market withdrawal or correction in any country in the Territory. Regado will make available to
NovaMedica, upon request, all of the other Party’s pertinent records that NovaMedica may reasonably request to assist it in effecting any recall or market withdrawals. 

  
 -14-

 5. INVENTIONS 

5.1 Joint Inventions. All patents and patent applications in the Territory disclosing Joint Inventions shall be owned by
NovaMedica and all patents and patent applications outside of the Territory disclosing Joint Inventions shall be owned by Regado. All Know-How arising under this Agreement (“Arising Know-How”) shall be owned jointly by the Parties, subject
to an exclusive, non-royalty bearing sublicensable license from (i) Regado to NovaMedica to use the Arising Know-How in the Territory and (ii) NovaMedica to Regado to use the Arising Know-How outside of the Territory, in each case,
consistent with the TTA and this Agreement. Disclosure of Joint Inventions. 
 5.2 Disclosure of Joint
Inventions. The JCC, shall within a reasonable time after the Effective Date establish a mutually agreeable procedure for determining and documenting inventorship of any invention initially put forth as a Joint Invention, provided that such
determination shall be made in accordance with applicable laws and regulation of the United States and Russia. Consistent with the TTA, all potentially patentable inventions either or both Parties believe to be Joint Inventions arising hereunder
will be promptly disclosed to the JCC. Upon the identification of a Joint Invention, the JCC shall (i) promptly discuss the desirability of filing a priority patent application covering such Joint Invention (the “Priority
Application”). The JSC, with appropriate advice of patent counsel reasonably acceptable to the JDC. 
 5.3
Prosecution and Maintenance: 
 5.3.1 Priority Application. Consistent with the TTA, Regado shall have
the first right to file and be responsible for and control the Prosecution and Maintanance of the Priority Application, using patent counsel reasonably acceptable to the JCC, subject to the limitation that Regado cannot abandon the Priority
Application or fail to file an application under the Patent Cooperation Treaty (“PCT Application”) claiming priority thereto without the consent of the JCC. The Parties shall share equally in the cost of preparing and filing the Priority
Application and shall coordinate to ensure that all deadlines are met, including any deadline to file a PCT Application. 

5.3.2 PCT Application. Regado shall have the first right to file and be responsible for and control the Prosecution and
Maintenance of the PCT Application, using patent counsel reasonably acceptable to the JCC. Regado shall provide NovaMedica with a draft of the PCT Application prior to filing, permitting NovaMedica the opportunity to provide comments. Unless
otherwise agreed to by the Parties, the PCT application will name NovaMedica as applicant for designated state within the Territory and Regado as applicant for designated state outside of the Territory. The Parties shall share equally in the cost of
preparing and filing the PCT Application. 
 5.3.3 National Phase Applications. Consistent with the TTA,
NovaMedica will be responsible for Prosecution and Maintenance of any Patent Right in the Territory claiming priority to the PCT Application or the Priority Application (“NovaMedica Arising Patent Right”), including any costs related
thereto, using patent counsel of its choosing. 

  
 -15-

 
Regado will be responsible for Prosecution and Maintenance of any patent application filed outside of the Territory claiming priority to the PCT (“Regado Arising Patent Right”),
including any costs related thereto, using patent counsel of its choosing. The Parties shall reasonably cooperate through the JCC with respect to Prosecution and Maintenance of the NovaMedica Arising Patent Rights and the Regado Arising Patent
Rights (collectively, the “Arising Patent Rights”), including (i) a receiving Party promptly providing the other Party with all received information reasonably believed to be necessary for the other Party to comply with any duty of
candor/duty of disclosure requirement with respect to the Arising Patent Rights in any jurisdiction; (ii) each responsible Party keeping the other Party advised of the status of the Arising Patent Rights, including, without limitation, grant of
any Arising Patent Right, and providing advance copies of any material communications to and from any applicable patent offices, actual or prospective filings or submissions or correspondence related to any such Arising Patent Right for review and
comment by the other Party. 
 5.3.4 Abandonment of NovaMedica Patent Rights. Consistent with the TTA, if
NovaMedica (or its designee(s) elects in its sole discretion not to Prosecute or Maintain a NovaMedica Patent Right, it shall inform Regado in writing at least ninety (90) calendar days before any deadline applicable to the Prosecution or
Maintenance, or any other date by which action must be taken to establish or preserve such NovaMedica Patent Right and in such case, Regado shall have the right, but not the obligation, to pursue the filing or support the continued Prosecution or
Maintenance of such NovaMedica Patent Right. 
 5.4 Disputes. Any disputes between the Parties related to this
Section 5 shall be brought to the attention of the JCC for resolution. Each Party shall be free to exploit its respective Arising Patent Rights without restriction, consistent with the TTA. 

5.5 Patent Due Diligence. Each Party agrees to bring to the attention of the other Party in a timely manner any Third Party
patent or patent application it discovers, or has discovered, and which the Party reasonably believes is material to the Development or Commercialization of Compounds and/or Covered Products. Each Party is responsible for conducting any freedom to
operate searches and analyses relevant to their Development and/or Commercialization of Covered Products and/or Compound, including any costs related thereto, but will provide any information obtained as a result with relevance to the Development
and/or Commercialization of Covered Products and/or Compound. 
 6. INFORMATION AND ADVERSE DRUG EVENTS AND REPORTS

 6.1 Information. Regado and NovaMedica will disclose and make available to each other in a timely manner
all non-clinical, preclinical, clinical, regulatory, commercial and other information concerning the Covered Products and/or Compound and constituting Know-how, known by Regado and NovaMedica at any time during the Term of this Agreement. Each Party
will use Commercially Reasonable Efforts to disclose to the other Party all significant information related to the Covered Products and/or Compound and Development activity inside and outside of the Territory promptly after it is learned or its
significance is appreciated. Notwithstanding the foregoing, neither Party shall be obligated to disclose to the other Party confidential information about its products other than the Covered Products and/or Compound. 

  
 -16-

 6.2 Compliance. Each Party shall maintain a record of all non-medical and
medical product-related complaints it receives with respect to any Covered Product and/or Compound. Each Party shall notify the other Party of any complaint received by it in sufficient detail and in accordance with the timeframes and procedures for
reporting established by the JSC, and in any event in sufficient time to allow the Party that holds the applicable regulatory filing to comply with any and all regulatory requirements imposed upon it in any country. The Party that holds the
applicable regulatory filing in a particular country shall investigate and respond to all such complaints in such country with respect to any Covered Product as soon as reasonably practicable. All such responses shall be made in accordance with the
procedures established by the JSC and as required under applicable law of the country. The Party responsible for responding to such complaint shall promptly provide the other Party a copy of any such response. 

6.3 Adverse Drug Events. Each Party will be responsible for the safety surveillance and pharmacovigilance regulatory
obligations with respect to the Covered Product in those territories where it is the sponsor of non-clinical or clinical development, including but not limited to animal toxicology or pharmacology studies. The Parties agree to provide each other
with Adverse Event information and product complaint information relating to Covered Products as compiled and prepared by the Parties in the normal course of business in connection with the Development, Commercialization or sale of the Covered
Products, within time frames consistent with reporting obligations under applicable Law. All reports, updates, Adverse Events, product complaint and other information provided by one Party to the other Party under this Agreement (including under
this Section 6.3), shall be considered Confidential Information of the disclosing Party, subject to the terms of Section 7 hereof it being understood that the FDA or other applicable Regulatory Authority may publish information
relating to Adverse Events on its website. The Parties agree that the groups responsible for the safety surveillance and pharmacovigilance of the Covered Product at each company shall meet within one hundred eight (180) days following the
Effective Date to develop detailed procedures regarding the format, timing, and content of the safety information to be exchanged between the Parties, and shall meet periodically thereafter to update the procedures. 

6.4 Pharmacovigilance. The Parties agree that Regado and NovaMedica will, within ninety (90) days prior
to the date of the anticipated date of first Regulatory Approval in the Territory, conclude a Pharmacovigilance Agreement substantially in the form as provided in Schedule 4.3 to the TTA. 

  
 -17-

 7. TREATMENT OF CONFIDENTIAL INFORMATION 

7.1 Confidentiality; Exceptions. Except to the extent authorized by this Agreement or otherwise agreed in writing, the
Parties agree that the receiving Party (the “Receiving Party”) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement, Confidential Information in any
form (written, oral, photographic, electronic, magnetic, or otherwise) which is disclosed to it by the other Party (the “Disclosing Party”) or otherwise received or accessed by a Receiving Party in the course of performing its
obligations or exercising its rights under this Agreement, except to the extent that such Confidential Information: 
 7.1.1
was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed to, or learned by, the Receiving Party, or was otherwise developed independently by the Receiving Party, as evidenced by written records kept in
the ordinary course of business, or other documentary proof of actual use by the Receiving Party; 
 7.1.2 was generally
available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

7.1.3 became generally available to the public or otherwise part of the public domain after its disclosure and other than through
any act or omission of the Receiving Party in breach of this Agreement; or 
 7.1.4 was disclosed to the Receiving
Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others. 
 7.2 Authorized Disclosure. Except as expressly provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows:
(a) in connection with the performance of its obligations or exercise of rights granted or reserved in this Agreement (including the rights to Develop and Commercialize the Covered Products); (b) to the extent such disclosure is reasonably
necessary in filing or prosecuting patent, copyright, and trademark applications, prosecuting or defending litigation, complying with applicable governmental regulations, obtaining regulatory approval, conducting Clinical Trials, marketing Covered
Products, or otherwise required by Law; (c) in connection with the appraisal of Regado IP for the purpose of contributing such IP into the charter capital of NovaMedica or (d) to the extent mutually agreed to in writing by the Parties;
provided, however, that if a Receiving Party is required in litigation or by Law or regulation to make any such disclosure of a Disclosing Party’s Confidential Information it shall give reasonable advance notice to the Disclosing Party of such
disclosure requirement and, except to the extent inappropriate in the case of patent applications, shall use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed. In addition, a Receiving
Party may disclose Confidential Information of the Disclosing Party to any of its Affiliates and Permitted Transferees, or in connection with due diligence investigations by or on behalf of a Third Party in connection with a potential license,
collaboration, investment, merger, or acquisition with or by such Third Party, and, in the case of Regado, to Third Parties in connection with due diligence investigations by or on behalf of a Third Party in connection with a potential license,
collaboration, investment or other financing, merger, or acquisition with or by such Third Party; provided, however, in each of the foregoing cases, that such Third Party reasonably needs to have access to such Confidential Information agrees to be
bound by reasonable terms of confidentiality and non-use at least as stringent as those set forth in this Article 7, to limit such disclosure to only personnel having a need to know such information, and to return or certify to the Receiving Party
as to the destruction of such Confidential Information promptly after completing the due diligence investigation, negotiation, or transaction, as the case may be. 
 7.3 Disclosure of Agreement. No Party shall issue any press release or other public disclosure regarding this Agreement or the Parties’ activities hereunder, or any results or

  
 -18-

 
data arising hereunder, except with all the other Party’s prior written consent. Except to the extent required by Law or as otherwise permitted in accordance with this
Section 7.3, neither Party shall make any public announcements concerning this Agreement or the subject matter hereof without the prior express written consent of the other, which shall not be unreasonably withheld, conditioned or delay.
Notwithstanding the foregoing, to the extent information regarding this Agreement has already been publicly disclosed other than through any act or omission of a Party in breach of this Agreement, a Party may subsequently disclose the same
information to the public without the consent of the other Party. Each Party shall be permitted to disclose the terms of this Agreement, in each case under appropriate confidentiality provisions that are no stringent to those of this Agreement, to
any actual or potential acquirers, merger partners, and professional advisors. 
 7.4 Remedies. Each Party shall
be entitled to seek, in addition to any other right or remedy it may have, at law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened
violation of this Section 7. 
 8. REPRESENTATIONS, WARRANTIES AND COVENANTS 

8.1 Representations, Warranties and Covenants. Each Party hereby represents, warrants and covenants to the other Party as
of the Effective Date, as follows: 
 8.1.1 Such Party (i) has the power and authority and the legal right to enter
into this Agreement and to perform its obligations hereunder, and (ii) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement. This Agreement has been duly executed and delivered on behalf
of such Party and constitutes a legal, valid and binding obligation of such Party and is in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights
and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. 

8.1.2 Such Party is not aware of any pending or threatened litigation (and has not received any communication relating to any
pending or threatened litigation) that alleges that such Party’s activities related to this Agreement have violated, or that by conducting the activities as contemplated in this Agreement such Party would violate, any of the intellectual
property rights of any Person (after giving effect to the license grants in this Agreement). 
 8.1.3 All necessary
consents, approvals and authorizations of all regulatory and governmental authorities and other Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations
under this Agreement have been obtained (other than such consents, approvals and authorizations that the Parties will obtain in the course of performing their obligations under this Agreement). 

8.1.4 The execution and delivery of this Agreement the performance of such Party’s obligations hereunder (i) do not
conflict with or violate in any material way any 

  
 -19-

 
requirement of applicable Law, (ii) do not conflict with or violate any provision of the articles of incorporation, bylaws, limited partnership agreement or any similar instrument of such
Party, and (iii) do not conflict with, violate, or breach or constitute a default or require any consent under, any contractual obligation or court or administrative order by which such Party is bound. 

8.2 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY (AND THEIR RESPECTIVE AFFILIATES) HEREBY
DISCLAIMS ANY AND ALL WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING WITH RESPECT TO ANY TECHNOLOGY LICENSED UNDER THIS AGREEMENT, INCLUDING ANY WARRANTY OF QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE
OR PURPOSE. FOR THE AVOIDANCE OF DOUBT, NOTHING CONTAINED IN THIS SECTION 5.3 SHALL OPERATE TO LIMIT OR INVALIDATE ANY EXPRESS WARRANTY CONTAINED HEREIN. 
 9. INDEMNIFICATION 
 9.1 Indemnification by NovaMedica.
NovaMedica shall indemnify, defend, and hold Regado and its Affiliates, and each of their respective employees, officers, directors, and agents (individually or collectively, the “Regado Indemnitee(s)”) harmless from and against any
and all liability, damage, loss, cost, or expense (including reasonable attorneys’ fees) resulting from Third Party claims against Regado Indemnitee(s) arising out of or resulting from (a) any breach by NovaMedica, NovaMedica or Permitted
Transferee of any of the terms or provisions of this Agreement; (b) any breach of the representations, warranties, or covenants made by NovaMedica; (c) willful misconduct or negligence of NovaMedica, Permitted Transferee or any
subcontractors or sublicensees; provided, however, that such obligations pursuant to this Section 9.1 shall not apply to the extent such claim (i) arise out of breach by the Regado of its representations, warranties, or covenants set forth
in Section 8, above; or (ii) are based on actions taken or omitted to be taken by Regado in breach of its obligations under this Agreement; or (iii) result from the negligence or willful misconduct of any of the Regado Indemnitee(s).

 9.2 Indemnification by Regado. Regado shall indemnify, defend, and hold each NovaMedica and any
Permitted Transferee, and each of their respective agents, employees, officers, and directors (individually or collectively, the “NovaMedica Indemnitee(s)”), harmless from and against any and all from and against any and all
liability, damage, loss, cost, or expense (including reasonable attorneys’ fees) resulting from Third Party claims against NovaMedica Indemnitee(s) arising out of or resulting from any (a) breach by Regado of any of the terms or provisions
of this Agreement; (b) any breach of the representations, warranties, or covenants made by Regado; or (c) willful misconduct or negligence of Regado or any of its Affiliates; provided, however, that such obligations pursuant to this
Section 9.2 shall not apply to the extent such Third Party claim (i) arises out of breach by NovaMedica of its representations, warranties, or covenants set forth in Section 8, above; or (ii) are based on actions taken or omitted
to be taken by such NovaMedica in breach of its obligations under this Agreement; or (iii) result from the negligence or willful misconduct of any of NovaMedica Indemnitee(s). 

  
 -20-

 9.3 No Consequential Damages. IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS
AFFILIATES, ASSIGNEES, LICENSEES, OR SUCCESSORS) BE LIABLE TO THE OTHER PARTY (OR ANY OF THE OTHER PARTY’S AFFILIATES, ASSIGNEES, LICENSEES, OR SUCCESSORS) FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, WHETHER IN
CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY, OR OTHERWISE, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY BREACH THEREOF; PROVIDED, HOWEVER, THAT THIS SECTION 9.3 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY’S
INDEMNIFICATION OBLIGATIONS WITH RESPECT TO CLAIMS UNDER SECTION 9.1 OR 9.2, ABOVE. 
 9.4 Notification of Claims;
Conditions to Indemnification Obligations. As a condition to a Party’s (or, as the case may be, a NovaMedica Indemnitee’s or a the Regado Indemnitee’s) right to receive indemnification under this Section 9, it shall
(a) promptly notify the other party as soon as it becomes aware of any Third Party claim or suit for which indemnification may be sought hereunder, (b) reasonably cooperate, and make Commercially Reasonable Efforts to cause the individual
indemnitees to cooperate, with the indemnifying party in the defense, settlement, or compromise of such claim or suit, and (c) permit the indemnifying party to control the defense, settlement, or compromise of such claim or suit, including the
right to select defense counsel; provided, however, the indemnified party shall have the right to join any defense with its own counsel at its own expense, or if the indemnifying party declines or fails to assert its intention to defend such action
within sixty (60) days of receipt/sending of notice under this Section 9.4, then the indemnified party shall have the right, but not the obligation, to defend such action. In no event, however, may the indemnifying party compromise
or settle any claim or suit in a manner that admits fault or negligence on the part of the indemnified party (or any indemnitee) without the prior written consent of the indemnified party. The indemnifying party shall have no liability under this
Section 6 with respect to claims or suits settled or compromised by the indemnified party without the indemnifying party’s prior written consent. 
 10. TERM AND TERMINATION 
 10.1 Term and Expiration. The term
of this Agreement (the “Term”) shall commence on the Effective Date and, unless earlier terminated as expressly provided in this Section 10 or extended by mutual consent of the Parties, shall remain in full force and
effect for the earlier of (i) three (3) years following the First Commercial Sale or (ii) or nine (9) years from the Effective Date. 
 10.2 Termination upon termination of TTA. This Agreement shall automatically terminate upon termination of the TTA. 
 10.3 Termination of the Agreement for Convenience. NovaMedica shall have the right, any time during the Term and at its convenience, to terminate this Agreement in its entirety upon ninety
(90) calendar days prior written notice to Regado. Except as otherwise provided in this Agreement, Regado shall have no right during the Term to revoke or unilaterally terminate the Agreement, in whole or in part. 

  
 -21-

 10.4 Effects of Termination. 

10.4.1 Return of Confidential Information. Upon termination, but not expiration, of this Agreement, each Party
shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party’s possession or control containing Confidential Information of the other Party; provided, however, that each Party shall be
entitled to retain one (1) copy of the other Party’s Confidential Information (subject to a continuing obligation of confidentiality) for the sole purpose of monitoring compliance with the terms of this Agreement, and all Confidential
Information received by Regado may continue to be used by it insofar as it relates to the Regado or any Covered Product. 

10.4.2 Accrued Obligations. Termination of this Agreement for any reason shall not release either Party of any obligation
or liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination. 
 10.4.3 Non-Exclusive Remedy. Termination of this Agreement by a Party shall be without prejudice to other remedies such Party may have at law or equity. 

10.4.4 Survival. The provisions of Sections 1, 4.4, 5, 6 – 13 shall survive termination of this Agreement.
Furthermore, any other provision that by its nature is intended to survive expiration and/or termination of this Agreement shall survive. 
 11. DISPUTE RESOLUTION 
 The provisions of this Section 11
concern resolution of disputes between the Parties, which shall be resolved in accordance with dispute resolution procedures set forth below: 
 11.1 Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during the Term that relate to either Party’s rights and/or obligations hereunder.
It is the objective of the Parties to establish procedures to facilitate the prompt resolution of disputes relating to or arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event that
the Parties are unable to resolve such dispute within thirty (30) days from the day that one Party had designated to the other an issue as a dispute, then either Party shall have the right to escalate such issue to senior management as set
forth in Section 11.2, below. 
 11.2 Escalation to Senior Representatives. Either Party may, by written
notice to the other Party, request that a dispute that remained unresolved for a period of thirty (30) days as set forth in Section 11.1, above, be resolved by the Chief Executive Officer of NovaMedica (or such person’s
designee) (the “NovaMedica Representative”) and the Chief Executive Officer of Regado (or such person’s designee) (the “the Regado Representative”) (collectively, the “Representatives”) within
sixty (60) days of the Representatives’ first consideration of such dispute, but in all cases within ninety (90) days after a Party’s written request for resolution by the Representatives. If the Representatives cannot resolve
such dispute within such ninety (90) day period, either Party may proceed to enforce any and all of its rights with respect to such dispute in accordance with Section 11.3 or Section 11.4, below, as applicable.

  
 -22-

 11.3 Arbitration. 

11.3.1 Any dispute, controversy or claim arising out of, relating to or in connection with, this Agreement, including any dispute
regarding the interpretation, validity or termination or the performance or breach of this Agreement, as well as any non-contractual obligation arising out of or in connection with it, which is not resolved by mutual agreement, above, shall be
finally settled by binding arbitration under the Rules of the London Court of International Arbitration (the “LCIA”) then in effect. 
 11.3.2 The arbitration shall be conducted by arbitrators, of whom one shall be nominated by NovaMedica and one shall be nominated by Regado. The two arbitrators so appointed shall nominate the
third arbitrator, who shall act as chairman of the Arbitral Tribunal. In the event that an arbitrator is not appointed pursuant to the foregoing provisions within the time period prescribed under the Rules of the LCIA or within the time-period
agreed upon by the parties to the arbitration, upon request of either party to the arbitration, such arbitrator shall instead be appointed by the Court of the LCIA. 
 11.3.3 The Parties shall use good faith efforts to complete arbitration under this Section 11.3 within one hundred eighty (180) days following the initiation of such arbitration. The
Arbitral Tribunal shall permit full and complete discovery, both written and oral by deposition and shall establish reasonable additional procedures to facilitate and complete such arbitration within such one hundred eighty (180) day period.
The place of arbitration will be London, England. The language of the arbitration, and all proceedings thereunder, including all discovery (both written and oral) will be English. 

11.3.4 By agreeing to arbitration, the Parties do not intend to deprive any court of competent jurisdiction of its ability to
issue any form of provisional remedy, including but not limited to a preliminary injunction or attachment in aid of the arbitration, or order any interim or conservatory measure. A request for such provisional remedy or interim or conservatory
measure by a Party to a court or other government entity shall not be deemed a waiver of this agreement to arbitrate. 

11.3.5 The award rendered by the Arbitral Tribunal, which shall cover which party shall bear the costs of the arbitration in
accordance with subsection (e) below, shall be final and binding on the parties. Judgment on the award may be entered in any court of competent jurisdiction. 
 11.3.6 The costs of such arbitration, including administrative and fees of the arbitrators comprising the arbitration panel, shall be shared equally by the Parties, and each Party shall bear its
own expenses and attorney’s fees incurred in connection with the arbitration; provided, however, that the arbitration panel may direct that the costs and attorney fees paid by one party be reimbursed by the other party. The arbitration panel
shall consider the following factors in determining whether to award costs and attorney fees to be paid by one party to another party: (i) the conduct of the parties in the transactions or occurrences that gave rise to the dispute or claim,
including any conduct of a party that was reckless, willful, malicious, in bad faith or illegal; (ii) the objective reasonableness of the claims and defenses asserted by a party; (iii) the extent to which an award of costs and attorney
fees would deter 

  
 -23-

 
future bad faith claims or defenses; (iv) the objective reasonableness of the parties and the diligence of the parties and their attorneys during the proceedings; (v) the objective
reasonableness of the parties and the diligence of the parties in pursuing settlement of the dispute; and (vi) such other factors as the arbitration panel may consider appropriate under the circumstances. 

11.4 Provisional Remedies. Nothing in this Agreement shall limit the right of either Party to seek to obtain in any court
of competent jurisdiction any equitable or interim relief or provisional remedy, including injunctive relief, pending resolution under Sections 11.2 or 11.3, above, as applicable, that may be necessary to protect the rights or property
of that Party. Seeking or obtaining such equitable or interim relief or provisional remedy in a court shall not be deemed a waiver of the agreement to arbitrate. For clarity, any such equitable remedies shall be cumulative and not exclusive and are
in addition to any other remedies that either Party may have under this Agreement or applicable Law. 
 11.5
Remedies. In the event a Party is in breach of its obligations under this Agreement, and the breach is not remedied in accordance with the terms of this Agreement, the other Party shall be entitled to all remedies available in law or
equity, consistent with the terms of this Agreement, including without limitation, collection of damages, injunctive relief, and specific performance. 
 12. MISCELLANEOUS 
 12.1 Relationship of the Parties. Nothing
in this Agreement is intended or shall be deemed to constitute a partnership, agency, joint venture, or other relationship between the Parties. 
 12.2 Assignment. 
 12.2.1 Except as expressly provided
herein, neither this Agreement nor any interest hereunder shall be assignable nor any other obligation delegable, by either Party without the prior written consent of the other Party (not to be unreasonably withheld or delayed). Notwithstanding the
foregoing, each Party shall have the right to assign this Agreement in whole without the consent of the other Party to (X) any Affiliate (Y) Permitted Transferee or (Y) a successor to substantially all of the business of the assigning
Party to which this Agreement relates (“Successor”), whether by merger, sale of stock, sale of assets or similar transaction, operation of law, or otherwise; provided, however, that an Affiliate or Successor must accept all rights
and obligations under this Agreement and the Ancillary Agreements. 
 12.2.2 Any permitted assignment under this
Section 12.2 shall relieve the assigning Party of any and all of its responsibilities or obligations hereunder, provided that, as a condition of such assignment, the assignee agrees in writing to be bound by all obligations of the assigning
Party hereunder. 
 12.2.3 This Agreement shall be binding upon the successors and permitted assigns of the Parties.

 12.2.4 Any assignment not in accordance with this Section 12.2 shall be void. 

  
 -24-

 12.3 Performance by NovaMedica and Permitted Transferee. Notwithstanding
anything to the contrary in this Agreement, NovaMedica shall have the right to have any of its obligations hereunder performed, or its rights hereunder exercised, by, any of its Affiliates or Permitted Transferees, and the performance of such
obligations by any such Affiliate(s) or Permitted Transferee(s) shall be deemed to be performance by NovaMedica and, provided that (a) any NovaMedica or Permitted Transferee that agrees to perform or exercise on NovaMedica behalf any of
NovaMedica’s obligations or rights under this Agreement agrees that Regado is an intended third party beneficiary of any such performance or exercise and (b) NovaMedica provides Regado with a copy of such agreement between NovaMedica and
the Permitted Transferee, thereafter NovaMedica shall not be responsible to Regado for performance of such obligation(s) under this Agreement and any failure of such Permitted Transferee in performing obligations shall be not deemed to be a failure
by NovaMedica to perform such obligations. 
 12.4 Actions. Each Party agrees to execute, acknowledge, and deliver
such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 12.5 Force Majeure. Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such
failure or delay is caused by acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, failure or delay of transportation, default by suppliers or unavailability of raw materials, governmental
acts or restrictions or any other reason which is beyond the control of the respective Party. 
 12.6 Amendments.
No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party. 

12.7 Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing
or interpreting any of the provisions of this Agreement. 
 12.8 Governing Law. This Agreement shall be governed
by and interpreted in accordance with the Laws of the State of New York, USA, excluding the application of any conflict of laws principles that would require application of the Law of another jurisdiction; provided, however, that matters of
intellectual property law shall be determined in accordance with the national intellectual property laws relevant to the intellectual property at issue. 
 12.9 Notices and Deliveries. Any notice, request, approval, or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been
sufficiently given if delivered in person, transmitted, by facsimile (receipt verified), or by express courier service (signature required) to the Party to which it is directed at its address or facsimile number shown below or such other address or
facsimile number as such Party shall have last given by notice to the other Party. 

  
 -25-

			
	If to Regado, addressed to:	  	Regado Biosciences, Inc.
		  	120 Mountain View Boulevard, First Floor
		  	Basking Ridge, New Jersey, 07920 USA
		  	Attention: President and CEO
		  	Facsimile: XXX XXX XXXX
		
	With a copy to:	  	Lowenstein Sandler, LLP
		  	65 Livingston Avenue
		  	Roseland, New Jersey USA 07068
		  	Attention: Michael J. Lerner, Esq.
		  	Facsimile: 973-597-6395
		
	If to NovaMedica, addressed to:	  	NovaMedica, LLC
		  	125047 bldg 29/22
		  	1st Brestskaya Street
		  	Moscow
		  	Russian Federation
		  	Attention: CEO of LLC “D-Pharma”, Managing Company
		  	Vladimir Gurdus

 12.10 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement
in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations, and agreements contained in this Agreement
shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation, or agreement of either Party. 
 12.11 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this
Agreement is held to be prohibited by or invalid under applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good faith
effort to replace the invalid or unenforceable provision with a valid one that in its economic effect is most consistent with the invalid or unenforceable provision. 
 12.12 Transfer and Technology Agreement. The terms and conditions of the TTA are not changed, amended or modified through this Agreement and shall remain unchanged and in full force and
effect. All rights, powers and privileges of the Parties under this Agreement are in addition to any rights, powers and privileges granted to the Parties by the TTA. In the event of a conflict between the terms of this Agreement at the TTA, the TTA
shall control. 
 12.13 Assumptions. The terms and provisions in this Agreement have been negotiated and drafted
on the assumption by the Parties that there are no laws or regulations in the Territory that will prevent or significantly hinder NovaMedica or Permitted Transferees or Regado from performing their obligations and realizing their benefits as set
forth in this Agreement. If this assumption ultimately proves to be untrue, the Parties will use good faith efforts to make such revisions as are reasonable and equitable to the Parties and are in compliance with the laws and regulations of the
Territory. 

  
 -26-

 12.14 English as the Controlling Language for all Agreements. All notices and
other communications under this Agreement and any related agreements, including assignments, licenses, and/or sublicenses with NovaMedica and/or a Permitted Transferee, shall be in the English language. NovaMedica shall, furthermore, require that
any assignment, license, sublicense, or other agreement (i) having NovaMedica or a Permitted Transferee as a party and (ii) a copy of which is required by this Agreement to be provided a Party, shall be prepared in the English language,
which language shall govern the interpretation of, and any dispute regarding, the terms of that agreement. 
 12.15
Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile copy of this Agreement,
including the signature pages, will be deemed an original. 
 [Remainder of page intentionally left blank] 

  
 -27-

 IN WITNESS WHEREOF, each of the Parties have caused this Clinical Development and
Collaboration Agreement to be executed by its duly authorized representative as of the Effective Date. 
  

									
	REGADO BIOSCIENCES, INC.:	 		 	NOVAMEDICA LLC:
					
	By:	 	 /s/ David J. Mazzo
	 		 	By:	 	 /s/ Vladimir Gurdus

					
	Name:	 	David J. Mazzo	 		 	Name:	 	Vladimir Gurdus
					
	Title:	 	President & CEO	 		 	Title:	 	CEO of LLC “D-Pharma”
		 		 		 		 	Managing Company

  
 -28-

 Schedule 1.5-Compounds 

[*] 

  
 -29-

 Schedule 1.26 – Territory 

CIS states: 
  

	1.	Armenia 

  

	2.	Azerbaijan

  

	3.	Belarus 

  

	4.	Kazakhstan 

  

	5.	Kyrgyzstan 

  

	6.	Moldova

  

	7.	Russia

  

	8.	Tajikistan

  

	9.	Ukraine

  

	10.	Uzbekistan

 Non-CIS states:

  

	11.	Georgia 

  

	12.	Turkmenistan 

  
 -30-

 Schedule 3.7.1- 

List of Third Party Agreements 
 Third Party Licenses 
  

	 	•	 	 License Agreement, dated as of October 3, 2003, by and between Archemix Corp. and Regado Biosciences, Inc. 

 

	 	•	 	 License Agreement, dated as of November 18, 2004, by and between Duke University and Regado Biosciences, Inc. 

 

	 	•	 	 First Amendment, dated as of July 13, 2005, to License Agreement by and between Duke University and Regado Biosciences, Inc.

  

	 	•	 	 License Manufacturing and Supply Agreement, dated as of December 22, 2006, by and between Nektar Therapeutics AL, Corporation and Regado
Biosciences, Inc 

 Third Party Non-IP Agreements 

 

	 	•	 	 Supply and Service Agreement, dated July 13, 2006, by and between Regado Biosciences, Inc. and Agilent Technologies, Inc

  

	 	•	 	 Amendment to Supply and Service Agreement, dated July 22, 2011, by and between Regado Biosciences, Inc. and Agilent Technologies, Inc.

  

	 	•	 	 Clinical Supply Agreement, dated March 28, 2012, by and between Regado Biosciences, Inc. and Althea Technologies Inc.

  
 -31-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]